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Implantable cardioverter-deﬁbrillator (ICD) therapy is clearly
an effective therapy for selected patients in deﬁnable populations.
The beneﬁts and risks of ICD therapy are directly impacted by
programming and surgical decisions. This ﬂexibility is both a great
strength and a weakness, for which there has been no prior ofﬁcial
discussion or guidance. It is the consensus of the 4 continental
electrophysiology societies that there are 4 important clinical
issues for which there are sufﬁcient ICD clinical and trial data to
provide evidence-based expert guidance. This document system-
atically describes the greater than 80% (83%–100%, mean 96%)
required consensus achieved for each recommendation by ofﬁcial
balloting in regard to the programming of (1) bradycardia mode
and rate, (2) tachycardia detection, (3) tachycardia therapy, and
(4) the intraprocedural testing of deﬁbrillation efﬁcacy. Repre-
sentatives nominated by the Heart Rhythm Society (HRS), Eur-
opean Heart Rhythm Association (EHRA), Asian Paciﬁc Heart
Rhythm Society (APHRS), and the Sociedad Latinoamericana de
Estimulacion Cardiaca y Electroﬁsiologia (SOLAECE-Latin American
Society of Cardiac Pacing and Electrophysiology) participated in
the project deﬁnition, the literature review, the recommendation
development, the writing of the document, and its approval. The
32 recommendations were balloted by the 35 writing committee
members and were approved by an average of 96%.
The classiﬁcation of the recommendations and the level of
evidence follow the recently updated ACC/AHA standard [1,2].
Class I is a strong recommendation, denoting a beneﬁt greatly
exceeding risk. Class IIa is a somewhat weaker recommendation,
with a beneﬁt probably exceeding risk, and Class IIb denotes a
beneﬁt equivalent to or possibly exceeding risk. Class III is arecommendation against a speciﬁc treatment because either there
is no net beneﬁt or there is net harm. Level of Evidence A denotes
the highest level of evidence from more than 1 high-quality ran-
domized clinical trial (RCT), a meta-analysis of high-quality RCTs,
or RCTs corroborated by high-quality registry studies. Level of
evidence B indicates moderate-quality evidence from either RCTs
with a meta-analysis (B-R) or well-executed nonrandomized trials
with a meta-analysis (B-NR). Level of evidence C indicates ran-
domized or nonrandomized observational or registry studies with
limited data (C-LD) or from expert opinions (C-EO) based on
clinical experience in the absence of credible published evidence.
These recommendations were also subject to a 1-month public
comment period. Each society then ofﬁcially reviewed, com-
mented, edited, and endorsed the ﬁnal document and recom-
mendations. All author and peer reviewer disclosure information
is provided in Appendix A.
The care of individual patients must be provided in context of
their speciﬁc clinical condition and the data available on that
patient. Although the recommendations in this document provide
guidance for a strategic approach to ICD programming, as an
individual patient’s condition changes or progresses and addi-
tional clinical considerations become apparent, the programming
of their ICDs must reﬂect those changes. Remote and in-person
interrogations of the ICD and clinical monitoring must continue to
inform the programming choices made for each patient. The
recommendations in this document speciﬁcally target adult
patients and might not be applicable to pediatric patients, parti-
cularly when programming rate criteria.
Please consider that each ICD has speciﬁc programmable
options that might not be speciﬁcally addressed by the 32 dis-
tinctive recommendations in this document. Appendix B,
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the writing committee’s translations speciﬁc to each manufacturer
and is intended to best approximate the recommended behaviors
for each available ICD model.2. Bradycardia Mode and Rate Programming
2.1. Single- or Dual-Chamber Pacing Mode
2.1.1. Evidence
Because the ICD is primarily indicated for tachycardia therapy,
there might be some uncertainty regarding optimal bradycardia
management for ICD patients. Data from clinical studies ade-
quately address only the programmed mode rather than the
number of leads implanted, the number of chambers stimulated,
or how frequently the patients required bradycardia support. It is
of note that most information on pacing modes has been collected
from pacemaker patients, and these patients are clinically distinct
from ICD recipients. Dual-chamber pacing (atrial and ventricular)
has been compared with single-chamber pacing (atrial or ven-
tricular) in patients with bradycardia in 5 multicenter, parallel,
randomized trials, in 1 meta-analysis of randomized trials, and in
1 systematic review that also included 30 randomized crossover
comparisons and 4 economic analyses [3–9]. Meta analyses com-
paring dual- chamber to single-chamber ICDs did not evaluate
pacing modes [10,11]. Compared with single-chamber pacing,
dual- chamber pacing results in small but potentially signiﬁcant
beneﬁts in patients with sinus node disease and/or atrioven-
tricular block. No difference in mortality has been observed
between ventricular pacing modes and dual-chamber pacing
modes. Dual-chamber pacing was associated with a lower rate of
atrial ﬁbrillation (AF) and stroke [12]. The beneﬁt in terms of AF
prevention was more marked in trials comprised of patients with
sinus node disease. Although trends in favor of dual-chamber
pacing have been observed in some trials, there was no beneﬁt in
terms of heart failure (HF). In patients without symptomatic bra-
dycardia, however, the Dual Chamber and VVI Implantable Deﬁ-
brillator (DAVID) trial in ICD recipients showed that one speciﬁc
choice of dual-chamber rate-responsive (DDDR) programming
parameters led to poorer outcomes than VVI backup pacing, most
likely secondary to unnecessary right ventricular (RV) pacing. The
fact that RV stimulation was responsible was reinforced in the
DAVID II trial, in which AAI pacing was demonstrated to be non-
inferior to VVI backup pacing [13].
Approximately a quarter of patients with either sinus node
disease or atrioventricular block develop “pacemaker syndrome”
with VVI pacing usually associated with retrograde (ventricular to
atrial) conduction, which in turn is associated with a reduction in
the quality of life [14]. In crossover trials, symptoms of pacemaker
syndrome (dyspnea, dizziness, palpitations, pulsations, and chest
pain) were reduced by reprogramming to a dual-chamber mode
[14]. Dual-chamber pacing is associated with better exercise per-
formance compared with single-chamber VVI pacing without rate
adaptation, but produces similar exercise performance when
compared with rate-responsive VVIR pacing. Because of the
additional lead, dual-chamber devices involve longer implantation
times, have a higher risk of complications, and are more expensive.
However, because of the additional clinical consequences of
pacemaker syndrome and AF (and its sequelae), the overall cost
difference between single- and dual-pacing systems is moderated.
In patients with persistent sinus bradycardia, atrial rather than
ventricular dual-chamber pacing is the pacing mode of choice.
There is evidence for superiority of atrial-based pacing over ven-
tricular pacing for patients who require pacing for a signiﬁcant
proportion of the day. The evidence is stronger for patients withsinus node disease, in whom dual-chamber pacing confers a
modest reduction in AF and stroke, but not in hospitalization for
HF or death compared with ventricular pacing. In patients with
acquired atrioventricular block, large randomized parallel trials
were unable to demonstrate the superiority of dual-chamber
pacing over ventricular pacing with regard to hard clinical end-
points of mortality and morbidity [4,6–8]. The beneﬁt of dual-
chamber over ventricular pacing is primarily due to the avoidance
of pacemaker syndrome and to improved exercise capacity [14].
Even if it is a softer endpoint, pacemaker syndrome is associated
with a reduction in quality of life that justiﬁes the preference for
dual-chamber pacing when reasonable; thus, there is strong evi-
dence for the superiority of dual-chamber pacing over ventricular
pacing that is limited to symptom improvement. Conversely, there
is strong evidence of nonsuperiority with regard to survival and
morbidity. The net result is that the indications for programming
the dual- chamber modes are weaker and the choice regarding the
pacing mode should be individualized, taking into consideration
the increased complication risk and costs of dual- chamber devi-
ces. Because ICD patients usually do not require bradycardia sup-
port, with the exception of patients who require cardiac resyn-
chronization, programming choices should avoid pacing and in
particular avoid single ventricular pacing, if possible [15,16].3. Programming of Rate Modulation
The beneﬁt of rate response programming has been evaluated
in patients with bradycardia in 5 multicenter, randomized trials
and in 1 systematic review that also included 7 single-center
studies [17–22]. Most of these data were obtained from pacemaker
studies and must be interpreted in that light.
Although there is evidence of the superiority of VVIR pacing
compared with VVI pacing in improving quality of life and exercise
capacity, improvements in exercise capacity with DDDR compared
with DDD have been inconsistent. In 2 small studies on patients
with chronotropic incompetence comparing DDD and DDDR
pacing, the latter had improved quality of life and exercise capa-
city; however, a larger, multicenter randomized trial (Advanced
Elements of Pacing Randomized Controlled Trial [ADEPT]) failed to
show a difference in patients with a modest blunted heart rate
response to exercise [17–19]. In addition, DDDR programming in
cardiac resynchronization therapy (CRT) patients has the potential
to impair AV synchrony and timing. It should be noted that trials
evaluating CRT generally did not use rate- responsive pacing, and
many in fact avoided atrial stimulation using atrial sensed and
ventricular paced pacing modes with a lower base rate. However,
the Pacing Evaluation- Atrial Support Study in Cardiac Resyn-
chronization Therapy (PEGASUS CRT) trial is the exception and did
not demonstrate adverse impact on mortality and HF events [23].4. Sinus Node Disease
In patients with persistent or intermittent sinus node dys-
function or chronotropic incompetence, the ﬁrst choice is DDDR
with algorithms responding to intermittent atrioventricular con-
duction. There is sufﬁcient evidence for the superiority of VVIR
compared with VVI in improving quality of life and exercise
capacity. The evidence is much weaker in dual-chamber pacing
(DDDR vs DDD).
Although only an issue when there is some concomitant AV
block, the upper rate limit should be programmed higher than the
fastest spontaneous sinus rhythm to avoid upper rate limit beha-
vior. To avoid symptomatic bradycardia, the lower rate should be
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characteristics and the underlying cardiac substrate of the patient.5. Atrial Fibrillation and Atrioventricular Block
Patients with permanent AF and either spontaneous or AV
junctional ablation-induced high-degree atrioventricular block
have little to no chronotropic response to exercise; thus, VVIR
pacing is associated with better exercise performance, improved
daily activities, improved quality of life, and decreased symptoms
of shortness of breath, chest pain, and heart palpitations, com-
pared with VVI [20–22,24–26]. Therefore, rate-adaptive pacing is
the ﬁrst choice of pacing mode; ﬁxed-rate VVI pacing should be
abandoned in patients with permanent AF and atrioventricular
block. It is the experts’ opinion that the minimum rate can be
programmed higher (e. g., 70 bpm) than for sinus rhythm patients,
in an attempt to compensate for the loss of active atrial ﬁlling. In
addition, the maximum sensor rate should be programmed
restrictively (e. g., 110–120 bpm) to avoid “overpacing” (i.e., pacing
with a heart rate faster than necessary), which can be sympto-
matic, particularly in patients with coronary artery disease. In a
small study, however, it was found that rate-responsive pacing
could be safe and effective in patients with angina pectoris,
without an increase in subjective or objective signs of ischemia
[25]. The lower rate should be programmed on an individual basis,
according to the clinical characteristics and the underlying cardiac
substrate of the patient. The clinical beneﬁt of programming a
lower resting rate at night based on internal clocks has not been
evaluated in ICD patients. There is some concern that atrioven-
tricular junction ablation and permanent ventricular pacing might
predispose the patient to an increased risk of sudden cardiac death
(SCD) related to a bradycardia-dependent prolongation of the QT
interval. This risk might be overcome by setting the ventricular
pacing rate to a minimum of 80 or 90 bpm for the ﬁrst 1-2 months
following the atrioventricular junction ablation, then reducing it to
a conventional 60–70 bpm [27,28]. Not all patients with AF and
milder forms of atrioventricular block will require a high percen-
tage of ventricular pacing or have a wide QRS. Physicians should
consider the risk of increasing preexisting left ventricular (LV)
dysfunction with RV pacing vs improved chronotropic respon-
siveness and the potential value of CRT.6. Intact Atrioventricular Conduction
6.1. Right Ventricular Pacing
The results of a number of large-scale, prospective randomized
trials demonstrated a signiﬁcant reduction in AF in pacemaker
patients with atrial-based pacing (AAI or DDD) compared with
patients with ventricular-based pacing [4,8,29]. In the Mode
Selection Trial, which enrolled 2010 patients with sick sinus syn-
drome, the risk of AF increased linearly with the increasing per-
centage of RV pacing [30]. At the same time, deleterious effects of
RV pacing in patients with LV dysfunction (left ventricular ejection
fraction [LVEF] r40%) implanted with dual-chamber ICD systems
were observed in the Dual Chamber and VVI Implantable Deﬁ-
brillator (DAVID) trial, which included 506 ICD patients without
indications for bradycardia pacing. Patients within the DDDR-70
group (with paced and sensed atrioventricular delays of 170 and
150 ms, respectively, in most of the DDDR group patients) showed
a trend toward higher mortality and an increased incidence of HF
compared with the patients programmed to ventricular backuppacing—the VVI-40 group. Within the DDDR-70 group, there were
more cardiac events when the percentage of ventricular pacing
exceeded 40% (P¼ .09) compared with patients with 95% RV sti-
mulation (DDDR-70) or [31,32] However, a more detailed post hoc
analysis of the Inhibition of Unnecessary RV Pacing With Atrial-
Ventricular Search Hysteresis in ICDs (INTRINSIC RV) trial revealed
that the most favorable clinical results were not in the VVI groups
with the least percentage of RV pacing but in the subgroup that
had DDD pacing with longer atrioventricular delays and 11%–19%
of ventricular pacing. This parameter selection probably helped
patients to avoid exceedingly low heart rates while preserving
intrinsic atrioventricular conduction most of the time [31,33]. In
the Second Multicenter Automated Deﬁbrillator Implantation Trial
(MADIT II), a higher risk of HF was observed in patients who had a
greater than 50% burden of RV pacing [34]. In another large
observational study of 456 ICD patients without HF at baseline, a
high RV pacing burden (RV pacing more than 50% of the time) was
associated with an increased risk of HF events and appropriate ICD
shocks [35]. Optimally, RV stimulation should be avoided, but the
precise tradeoff between the percentage of ventricular pacing and
atrioventricular timing is unclear in non-CRT patients.7. Non-CRT Devices: Algorithms to Reduce Right Ventricular
Stimulation
The importance of reducing or avoiding RV pacing in ICD
patients with LV dysfunction was illustrated in the DAVID trial
[31]. The feasibility of algorithms designed to decrease the burden
of unnecessary ventricular pacing has been demonstrated in
patients with dual-chamber pacemakers [36–38]. These algo-
rithms usually provide functional AAI pacing with monitoring of
atrioventricular conduction and an automatic mode switch from
AAI to DDD during episodes of atrioventricular block. Some studies
directly compared various algorithms to decrease ventricular
pacing, showing that a “managed ventricular pacing” (MVP)
algorithm resulted in greater ventricular pacing reduction than an
“atrioventricular search” algorithm [39,40]: however, no rando-
mized studies comparing these two algorithms with respect to
important cardiovascular endpoints (e.g., HF, cardiac death) have
been performed. The results of the studies on these pacing algo-
rithms are summarized in Table 1.
Unnecessary RV pacing should be minimized by using speciﬁc
algorithms or programming longer atrioventricular delays, and
this process is more important for patients with a higher risk of AF
or who already have poorer LV function [49]. Patients with longer
baseline PR intervals have a higher risk of AF regardless of the
percentage of ventricular pacing or the length of the programmed
atrioventricular interval [50]. Use of the AAIR pacing mode with
exceedingly long atrioventricular conduction times can lead to
“AAIR pacemaker syndrome” and actually increases the risk of AF
compared with the DDDR mode, as was shown in the Danish
Multicenter Randomized Trial on Single Lead Atrial versus Dual-
Chamber Pacing in Sick Sinus Syndrome (DANPACE) [3,51].
Therefore, excessively long atrioventricular delays resulting in
nonphysiologic atrioventricular contraction patterns should be
avoided. The potential harm of atrial pacing with a prolonged
atrioventricular delay was also demonstrated in the MVP trial. In
the MVP trial, dual- chamber pacing with the MVP algorithm was
not superior to ventricular backup pacing (VVI 40 bpm) with
respect to HF events. After a follow-up of 2.4 years, there was an
apparent increase in HF events that was limited primarily to
patients with a baseline PR interval of 4230 ms (mean PR of 255–
260 ms) [42]. Long atrioventricular intervals also predispose the
Table 1
Inﬂuence of pacing modes and algorithms on clinical endpoints.
Study Patients (PM/
ICD)
Results and remarks
SAVE PACe, randomized multicenter
(2007) [41]
1065 (PM) 40% relative risk reduction of AF in the MVP group compared with DDD pacing (4.8% absolute risk reduction).
MVP, randomized multicenter (2011)
[42]
1030 (ICD) No superiority of MVP over VVI-40 in terms of AF, VT/VF, quality of life, HF.
Steinbach et al, retrospective single-
center (2011) [43]
102 (PM) In patients over 75 years of age, MVP showed lower rates of HF episodes and all-cause mortality than conventional
DDD pacing
long-MinVPACE, randomized single-
center (2011) [44]
66 (PM) Less RV pacing, less AF burden in MinVP group patients compared with DDDR (mean 12.8 vs 47.6%). Chosen AV/PV
delay (150/130 ms) was probably too short in the DDDR (control) group.
Generation MVP, observational mul-
ticenter (2012) [45]
220 (PM) Signiﬁcantly fewer atrial arrhythmias when programmed to MVP compared with DDD.
PreFER MVP, randomized multi-
center (2014) [46]
605 (556PM,
49 ICD)
No difference between cardiovascular hospitalization, AF, and the composite of death and hospitalization between
the MVP and DDD groups. The authors stated that “patients were enrolled upon elective replacement of the
device, and were healthy enough to survive the ﬁrst device without experiencing a signiﬁcant decrease in LV
function.”
MINERVA, randomized multicenter
(2014) [47]
1300 (PM) AF burden: no superiority of MVP pacing compared with the DDDR mode (AV/ PV delay 4180/210 ms in greater
than 60% of patients, 53% of RV pacing). MVP in combination with atrial antitachycardia pacing was superior to
both DDDR and MVP-only.
COMPARE, randomized multicenter
(2014) [48]
385 (PM) Lower percentage of ventricular pacing (%VP) in the MVP group compared with the SearchAVþ group. A trend in
the correlation between %VP and AT/AF burden.
AT¼atrial tachycardia; HF¼heart failure; MVP¼Managed Ventricular Pacing; PM¼pacemaker.
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nonreentrant VA synchrony,” or “atrioventricular desynchroniza-
tion arrhythmia,” which manifest as mode switching but which
also cause sustained episodes with poor hemodynamics [52]. Thus,
based on the available data, it appears that atrial pacing with
excessively long atrioventricular delays should be avoided.
Algorithms that minimize ventricular pacing sometimes lead to
inadvertent bradycardia or spontaneous premature, beat-related
short-long-short RR interval sequences with proarrhythmic
potential [53–55]. However, in a study retrospectively analyzing
the onset of ventricular tachycardia (VT) in ICD patients, the MVP
mode was less frequently associated with the onset of VT com-
pared with the DDD and VVI modes [54]. Atrioventricular decou-
pling (greater than 40% of atrioventricular intervals exceeding
300 ms) was observed in 14% of the ICD patients in the Marquis
ICD MVP study, which might have a negative effect on ventricular
ﬁlling [56].
In ICD patients with structural heart disease, spontaneous
atrioventricular conduction can become prolonged instead of
shortening, with increased atrial paced heart rates [33]. This out-
come frequently leads to a higher percentage of ventricular paced
complexes. In view of the results of the ADEPT trial, which failed to
demonstrate the clinical superiority of combined rate modulation
and DDD pacing, the need for and aggressiveness of sensor-driven
rate responses should be individualized or eliminated [19]. Rate-
dependent shortening of atrioventricular delay could have the
same effect and should usually be avoided.
Patients with hypertrophic cardiomyopathy represent a small
but intricate subset of the ICD population for whom pacing has not
been demonstrated to be a consistently effective treatment for
outﬂow tract obstruction. However, according to the 2011 ACCF/
AHA Hypertrophic Cardiomyopathy Guideline, dual-chamber ICDs
are reasonable for patients with resting LV outﬂow tract gradients
more than 50 mm Hg, and who have indications for ICD implan-
tation to reduce mortality [57]. In these patients, atrioventricular
delays should be individually programmed to be short enough to
achieve RV preexcitation and decrease LV outﬂow tract gradient,
but not too short, which would impair LV ﬁlling; usually in the
ranges of 60–150 ms [58,59]. There are few studies of pacing
modes in these patients, and they are limited by small numbers
and the failure to quantify important cardiac outcomes.In conclusion, atrioventricular interval programming and
choosing between DDDR and MVP or other atrioventricular
interval management modes should be performed on an indivi-
dual basis. The goal is to minimize the percentage of RV pacing and
to avoid atrial-based pacing with atrioventricular intervals
exceeding 250–300 ms leading to atrioventricular uncoupling. In
patients with prolonged PR intervals and impaired LV function,
biventricular pacing can be considered.8. Cardiac Resynchronization Therapy: Consistent Delivery of
Ventricular Pacing
CRT in combination with a deﬁbrillator device (CRT-D)
improves survival and cardiac function in patients with LV systolic
dysfunction, prolonged QRS duration, and mild-to- severe HF [60–
62]. The beneﬁcial effect of CRT-D compared with ICD is likely to
be derived from biventricular pacing, with a decrease in dyssyn-
chrony and an improvement in cardiac function. The percentage of
biventricular pacing capture in the ventricles can be negatively
inﬂuenced by a number of factors, including atrial tachyar-
rhythmias, premature ventricular complexes, and programming of
the atrioventricular delay, giving way to the intrinsic conduction of
the patient and a reduced percentage of biventricular pacing.
Some large observational studies have investigated the optimal
level of biventricular pacing percentage and found a higher per-
centage to be associated with more pronounced CRT beneﬁts.
An optimal CRT beneﬁt was observed with a biventricular pacing
percentage as close to 100% as possible [63–66].
In the analysis of the left bundle branch block population in the
MADIT-CRT trial, those patients with less than 90% biventricular
pacing had similar rates of HF and death compared with the patients
randomized to no CRT. By contrast, biventricular pacing exceeding
90% was associated with a beneﬁt of CRT-D in terms of HF or death
when compared with ICD patients and no CRT. Biventricular pacing
97% and greater was associated with a further reduction in HF or
death and a signiﬁcant reduction in death alone. Consistently, every
1% increase in biventricular pacing percentage was associated with a
6% risk reduction in HF or death, a 10% risk reduction in death alone,
and an increase in LV reverse remodeling [67]. Therefore, in ICD
patients with biventricular pacing, it can be beneﬁcial to adjust the
therapy to produce the highest achievable percentage of ventricular
In
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hospitalization. Approaches to increasing the percentage of biven-
tricular pacing include programming shorter but hemodynamically
appropriate atrioventricular delays and minimizing atrial and ven-
tricular ectopic activity and tachyarrhythmias.
Optimizing the location of ventricular pacing sites and the timing
of the pacing pulses can signiﬁcantly improve cardiac hemody-
namics in CRT patients. Echocardiographic optimization of atrio-
ventricular delays in CRT patients can alleviate HF symptoms and
increase exercise capacity compared with nominal programming,
particularly when approaching nonresponding populations [68].
However, echocardiographic optimization in the PROSPECT study
did not support this approach in a randomized trial, and the Fre-
quent Optimization Study Using the QuickOpt Method (FREEDOM)
trials failed to provide evidence supporting the beneﬁt of CRT opti-
mization and did not demonstrate superiority of the respective
algorithms over nominal or empiric programming [69–71]. There
are limited data supporting the use of LV- only stimulation in a small
subset of patients who fail to respond to biventricular stimulation
[72]. Adaptive CRT (aCRT) is an algorithm that periodically measures
intrinsic conduction and dynamically adjusts CRT pacing para-
meters. The algorithm withholds RV pacing when intrinsic electrical
conduction to the RV is normal and provides adjustment of CRT
pacing parameters based on electrical conduction. A prospective,
multicenter, randomized, double-blind clinical trial demonstrated
the safety and efﬁcacy of the aCRT algorithm [73]. This algorithm can
increase the longevity of the implantable device and replace a
manual device optimization process with an automatic ambulatory
algorithm, although echo optimization might still be needed, at least
in nonresponders. The Clinical Evaluation on Advanced Resynchro-
nization (CLEAR) study assessed the effects of CRT with auto-
matically optimized atrioventricular and interventricular delays,
based on a peak endocardial acceleration (PEA) signal system. PEA-
based optimization of CRT in patients with HF signiﬁcantly increased
the proportion of patients who improved with therapy during fol-
low- up, mainly through an improved New York Heart Association
(NYHA) class [74].In
In
InInBradycardia Mode and Rate Pro-
gramming RecommendationsClass of Recom-
mendationLevel of
EvidenceICD patients who also have
sinus node disease and
guideline-supported indications
for a bradycardia pacemaker, it
is beneﬁcial to provide dual-
chamber pacing to reduce the
risk of AF and stroke, to avoid
pacemaker syndrome, and to
improve quality of life.I B-Rsingle- or dual-chamber ICD
patients without guideline-
supported indications for bra-
dycardia pacing, adjusting the
pacing parameters is recom-
mended so that ventricular sti-
mulation is minimized to
improve survival and reduce HF
hospitalization.I B-RICD patients who have sinus
rhythm, no or only mild LV
dysfunction, and atrioven-
tricular block where ventricular
pacing is expected, it is reason-
able to provide dual-chamberIIa B-Rpacing in preference to single-
chamber ventricular pacing to
avoid pacemaker syndrome and
to improve quality of life.
ICD patients who have sinus
rhythm, mild-to-moderate LV
dysfunction, and atrioven-
tricular block where ventricular
pacing is expected, it is reason-
able to provide CRT in pre-
ference to dual-chamber ven-
tricular pacing to improve the
combination of HF hospitaliza-
tion, LV enlargement, and death.IIa B-RICD patients who have chron-
otropic incompetence, it can be
beneﬁcial to program the ICD to
provide sensor-augmented rate
response, especially if the
patient is young and physically
active.IIa B-NRdual-chamber ICD patients
with native PR intervals of
230 ms or less, it can be bene-
ﬁcial to program the mode,
automatic mode change, and
rate response so that the
patient’s native atrioventricular
conduction minimizes ven-
tricular pacing.IIa B-Rbiventricular pacing ICD
patients, it can be beneﬁcial to
adjust the therapy to produce
the highest achievable percen-
tage of ventricular pacing, pre-
ferably above 98%, to improve
survival and reduce HF
hospitalization.IIa B-NRbiventricular pacing ICD
patients, it can be reasonable to
activate the algorithms provid-
ing automatic adjustment of
atrioventricular delay and/or
LV-RV offset to obtain a high
percentage of synchronized
pacing and reduce the incidence
of clinical events.IIb B-R9. Tachycardia Detection Programming
Following signiﬁcant technological changes in ICDs in recent
years, the concept of optimal ICD programming has changed dra-
matically. From the dawn of this therapy in the early 1980s to the
ﬁrst decade of the 21st century, the rapid detection and treatment
of VT and ventricular ﬁbrillation (VF) have been stressed. The
argument for rapid detection of VT and VF derived from a number
of factors. Initial skepticism regarding the feasibility of sudden
death prevention with ICDs, the fact that early ICD patients had all
survived one or more cardiac arrests, concern for undersensing
and underdetection (of VF in particular), demonstration of an
increasing deﬁbrillation threshold with prolonged VF duration,
and the increased energy requirement of monophasic deﬁbrilla-
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detection and the shortest possible time to initial therapy [75–77].
The initial generations of ICDs did not record and save electro-
grams (EGMs), leading to a reduced appreciation for the frequency
and impact of inappropriate shocks. With the advent and then
dominance of primary prevention indications, avoidable shocks
assumed a relatively larger proportion of total therapy [78–83].
Gradually, publications have increased awareness of the frequency
and the diverse range of adverse outcomes associated with
avoidable ICD therapy, and have demonstrated that avoidable ICD
shocks can be reduced by evidence-based programming of the
detection rate, detection duration, antitachycardia pacing (ATP),
algorithms that discriminate supraventricular tachycardia (SVT)
from VT, and speciﬁc programming to minimize the sensing of
noise [81–92].10. Duration Criteria for the Detection of Ventricular
Arrhythmia
Until recently, default device programming used short- dura-
tion “detection” criteria that varied by manufacturer and a
tachycardia rate of approximately 2.8 to 5 seconds before either
ATP or charging (including detection time plus duration or number
of intervals) [82,93]. With increased awareness of the potential
harm from inappropriate shocks and the realization from stored
pacemaker EGMs that even long episodes of VT can self-terminate,
a strategy of prolonged detection settings has been explored. This
strategy allows episodes to self-terminate without requiring
device intervention and reduces inappropriate therapy for non-
malignant arrhythmias. The beneﬁt of programming a prolonged
detection duration (30 of 40 beats) was ﬁrst reported in the Pre-
vention Parameters Evaluation (PREPARE) study on exclusively
primary prevention subjects (n¼700), and compared outcomes to
a historical ICD cohort programmed at “conventional detection
delays” with about half programmed to 12 of 16 intervals within
the programmed detection zone and half to 18 of 24 intervals [94].
The programming in PREPARE demonstrated a signiﬁcant reduc-
tion in inappropriate shocks for supraventricular arrhythmia and
in avoidable shocks for VT. In addition, a composite endpoint was
reduced as well: the morbidity index, which consists of shocks,
syncope, and untreated sustained VT. Within the limitations of a
nonrandomized study, it was concluded that extending detection
times reduces shocks without increasing serious adverse sequelae.
In 2009, the Role of Long-Detection Window Programming in
Patients with Left Ventricular Dysfunction, Non- Ischemic Etiology
in Primary Prevention Treated with a Biventricular ICD (RELE-
VANT) study conﬁrmed and expanded the results of the PREPARE
trial in a cohort of 324 primary prevention CRT-D patients with
nonischemic cardiomyopathy [95]. The subjects were treated with
simpliﬁed VT management, which implies much longer detection
for VF episodes (30 of 40) compared with the control group (12 of
16) and a monitor-only window for VT. As in PREPARE, the RELE-
VANT study group experienced a signiﬁcantly reduced burden of
ICD interventions (81% reduction) without increasing the inci-
dence of syncope. Fewer inappropriate shocks and HF hospitali-
zations were reported in the RELEVANT study group compared
with the control group.
The Multicenter Automatic Deﬁbrillator Implantation Trial:
Reduce Inappropriate Therapy (MADIT-RIT), a 3- arm study, com-
pared a conventional programming strategy (a 1-second delay for
VF [equivalent to approximately 12 intervals including detection
plus delay] and a 2.5-second delay for VT detection [equivalent to
approximately 16 intervals including detection plus delay]) (Arm
A) to both a high-rate cutoff with a VF zone starting at 200 bpm
(Arm B) (discussed in section Rate Criteria for the Detection ofVentricular Arrhythmia and discussed as referenced in reference
[96].) and to a delayed therapy strategy with a 60- second delay for
rates between 170 and 199 bpm, a 12- second delay at 200 to
249 bpm, and a 2.5-second delay at 250 bpm (Arm C) [96]. The
MADIT-RIT population was exclusively primary prevention and
included approximately an equal proportion of nonischemic and
ischemic cardiomyopathy patients. All the patients were implan-
ted with either a dual-chamber ICD or a CRT-D programmed to
deliver ATP before charging. After a mean 1.4-year follow-up, the
prolonged detection group (Arm C) was associated with a reduc-
tion in treated VT/VF leading to a 76% reduction in the primary
endpoint of the ﬁrst inappropriate therapy (P The Avoid Delivering
Therapies for Non-Sustained Arrhythmias in ICD Patients III
(ADVANCE III) trial reported that a long detection was associated
with a highly signiﬁcant reduction of overall therapies (appro-
priate and inappropriate ATP and/ or shocks), inappropriate
shocks, and all-cause hospitalizations [97]. Importantly, like PRE-
PARE, RELEVANT, and MADIT-RIT, the extended detection duration
used in the ADVANCE III trial (30 of 40) did not negatively impact
the rate of syncopal events. There was no signiﬁcant difference in
mortality between the optimal and the conventional programming
groups. Compared with the MADIT-RIT trial, the ADVANCE III
control group had a longer detection duration (primarily in the VF
zone), and enrolled a larger cohort of subjects covering all ICD
types (single, dual, and CRT with ATP delivered during charging)
for both primary and secondary prevention indications. Finally, the
Programming Implantable Cardioverter-Deﬁbrillators in Patients
With Primary Prevention Indication (PROVIDE) trial randomized
1670 patients to conventional programming (12-beat detection in
each of 2 zones) or experimental programming (2 VT and 1 VF
zone requiring 25-, 18-, and 12-beat detection, respectively) [98].
PROVIDE observed a signiﬁcant 36% reduction in the 2-year all-
cause shock rate and an improved survival (hazard ratio [HR] 0.7;
95% conﬁdence interval [CI] 0.50–0.98; P¼ .036).
Whereas PREPARE, RELEVANT, MADIT-RIT, and PROVIDE only
enrolled primary prevention patients, a subset of the ADVANCE III
study evaluated the efﬁcacy and safety of a long-detection
approach in secondary prevention patients who have a known
higher burden of arrhythmic episodes. In this particular subset of
25% of the enrolled patients, ADVANCE III reported that a long
detection duration reduced the overall therapies delivered, pri-
marily due to a signiﬁcant 36% reduction in appropriate shocks
[99]. Syncopal episodes related to arrhythmic events and deaths
were similar between the 2 groups.Following shortly on the heels
of these trials, 2 meta-analyses including the above studies were
published in 2014. Tan et al presented the data from the RELE-
VANT, PREPARE, MADIT-RIT, ADVANCE III, PROVIDE, and EMPIRIC
trials [100,101]. A 30% reduction in the risk of death was found in
the therapy reduction group when including all 6 studies; how-
ever, similar results were observed when separately considering
the 4 randomized trials and the 2 observational studies. Data on
the appropriateness of shocks were available only for RELEVANT,
MADIT-RIT, ADVANCE III, and PROVIDE, and a 50% reduction in
inappropriate shock was observed without an increased risk of
syncope and appropriate shock.A meta- analysis evaluated the
impact of a prolonged arrhythmia detection duration on outcome
[102]—thus excluding the EMPIRIC trial (which used 18 of 24
intervals for VF detection), the PREPARE trial (which used a his-
torical control group), and the high-rate therapy arm of the
MADIT-RIT. Analyzing the cohort of patients enrolled in RELEVANT,
Arm C of MADIT-RIT, ADVANCE III, and PROVIDE, the meta-analysis
reported a reduction of overall burden of therapies, driven by the
greater than 50% reduction in appropriate and inappropriate ATP
and the 50% reduction in inappropriate shocks. A reduction in all-
cause mortality was observed without an increase in the risk of
syncope.All the reports above clearly stress the necessity to
Table 2
Tachycardia detection evidence.
Study Participants (N) Short detection
controls
Prolonged detection
intervention
Findings
PREPARE 1391 12 of 16 (58%) 30 of 40 Reduction in inappropriate shocks (SVT), avoidable shocks (VT), and”morbidity index”
Nonrandomized 18 of 24 (42%)
Primary prevention
RELEVANT 324 12 of 16 30 of 40 Reduction in inappropriate shocks (SVT), avoidable shocks (VT), and HF hospitalizations
Nonrandomized
Primary prevention
MADIT-
RIT
1500 2.5 s (170–
199 bpm)
60 s (170–199 bpm) Reduction in ﬁrst inappropriate therapy, ﬁrst appropriate therapy, appropriate ATP, and
inappropriate ATP; improved survival
Randomized 1 s (Z200 bpm) 12 s (200–249 bpm)
Primary prevention 2.5 s (Z250 bpm)
ADVANCE-
III
1902 18 of 24 30 of 40 Reduction in overall therapies, inappropriate shocks, and all-cause hospitalizations
Randomized
Primary & secondary
prevention
PROVIDE 1670 12 beats 25 beats (180–
214 bpm)
Reduction in all-cause shock rate; improved survival
Randomized 18 beats (214–
250 bpm)
Primary prevention 12 beats
(4250 bpm)
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for ICD programming. Moreover, they underline the importance of
choosing to reprogram the ICD rather than using the manu-
facturers’ out-of-the-box settings. A summary of the large com-
parative datasets of tachycardia detection is presented in Table 2.11. Limitations of Data on the Duration of Tachycardia
Required for Detection
Although the ﬁndings on the effect of tachycardia detection
duration are based on roughly 7000 patients, there are limitations.
Data on secondary prevention patients are limited to 25% of the
1902 patients enrolled in the ADVANCE III trial (n¼477). Although
this proportion is a fair representation of the real-world popula-
tion receiving an ICD, more data are needed to fully understand
the impact of a long-detection strategy in this subgroup of
patients. MADIT-RIT and RELEVANT did not include single-
chamber ICDs, and MADIT-RIT excluded patients with permanent
AF. The PROVIDE and MADIT-RIT trials were designed to assess the
time to ﬁrst therapy and not the overall rate of therapies. MADIT-
RIT, ADVANCE III, RELEVANT, and PROVIDE used devices from
3 different manufacturers with detection strategies leading to
different detection times, intervals, and deﬁnitions. Some manu-
facturers of ICDs are not represented at all in these trials. Pro-
gramming in the trial control groups was highly heterogeneous,
with time until ATP or charging for VF as varied as about 11–12
intervals (approximately 3.4 seconds at 200 bpm) in MADIT-RIT
and PROVIDE and 18 intervals (approximately 5.4 seconds) in
ADVANCE III. An approximate translation of the impact of the
number of intervals to detection and tachycardia cycle length (CL)
are listed in Table 3. A further limitation is the relatively short
duration and lack of inclusion of the patients with the most severe
illness receiving an ICD. This limitation minimizes the exposure to
relatively rare events that might occur in nonclinical trial, “real-
world” patients. Lastly, as ICD batteries deplete, the charge time
lengthens. The effect of such a delay to shock therapy in addition
to prolonged detection times has not been studied.
12. Rate Criteria for the Detection of Ventricular Arrhythmia
Ventricular tachyarrhythmia detection by implantable devices
is primarily based on heart rate. Heart rates can be extremely rapidduring ventricular tachyarrhythmias, and it is less likely that such
rates are achieved during supraventricular tachyarrhythmias—thus
making rate a powerful component of arrhythmia discrimination.
However, VT can also present slower rates in the range of those of
supraventricular tachyarrhythmias or even of sinus tachycardia.
Therefore, any rate cutoff will always imply a tradeoff between
maximizing sensitivity for ventricular tachyarrhythmia detection
at the expense of inappropriate detection of fast supraventricular
tachyarrhythmias and maximizing speciﬁcity at the expense of
some slow VTs going undetected [103].
Because ICD therapy was initially employed in secondary pre-
vention patients, the cutoff rate was usually tailored to a rate
slightly below that of the observed VT. With the development of ICD
use in primary prevention, the detection rate came into question
because there is no history of sustained tachycardia in these
patients. The recognition of a signiﬁcant rate of inappropriate
therapies in primary prevention studies, and their potentially
deleterious consequences, prompted the development of studies
that tested whether programming faster rate criteria reduced
avoidable ICD therapies, particularly shocks. In many of these stu-
dies, however, testing also involved programming parameters other
than rate, and those have been discussed as described below.
In the MADIT-RIT trial of primary prevention patients, conven-
tional therapy (rate cutoff 170 bpm, n¼514) was compared with a
“high-rate group” in which rate cutoff was 200 bpm (n¼500) [96].
The primary endpoint of ﬁrst occurrence of inappropriate therapy
was observed in 20% of the conventional group and in 4% of the
high-rate group (P follow-up of 1.4 years. ICD shocks occurred in 4%
and 2% of patients in the conventional and high-rate groups,
respectively. The proportion of patients with appropriate therapies
was also signiﬁcantly different (22% vs 9% in the conventional and
high-rate groups, respectively). It is important to note that all-cause
mortality in the conventional group (6.6%) was approximately
double that of the high-rate group (3.2%, P¼ .01).
In a single-center observational study, 365 primary prevention
patients were prospectively studied, with programming including
a single shock-only zone over 220 bpm [104]. During a mean
follow-up of 42 months, 11% of the patients (7% in the ﬁrst 2 years)
experienced appropriate shocks, and only 6.6% experienced inap-
propriate shocks. It was notable that in the monitoring zone over
170 bpm, self- limiting VT episodes were detected in 12% of the
Table 3
Approximating the time taken to detect 30 intervals using ﬁxed 8 of 10 interval detection plus adding a time delay, for a range of heart rates.
Arrhythmia characteristic Interval-based detection 8 of 10 interval detection, then delay
Beats per minute Cycle length (ms) Time to detect 30 intervals (s) Time to detect 8 intervals (s) Subsequent delay to approximate a 30-interval detection time
180 333 10.0 2.7 7.0
200 300 9.0 2.4 6.5
220 273 8.2 2.2 6.0
240 250 7.5 2.0 5.5
260 231 6.9 1.8 5.0
280 214 6.4 1.7 4.5
300 200 6.0 1.6 4.5
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was 17%, with one case of unexplained sudden death.
A recent primary prevention study revealed that there was
considerable overlap between the ventricular rates of supraven-
tricular and ventricular arrhythmias, and the majority of inap-
propriate shocks occurred at rates between 181 and 213 bpm [98].
These data also support the notion that for primary prevention
patients it is safe to increase the rate cutoff up to 200 bpm to
reduce these potentially avoidable therapies, a practice that was
also supported by the results of the MADIT-RIT trial.
In secondary prevention patients, no trial has randomized the
detection rate and compared outcomes. However, the ADVANCE III
Secondary Prevention substudy conﬁrmed the safety of not
programming therapy for rates patient- years [105]. Previously
published recommendations suggest a VT zone starting at 10 to
20 bpm slower than the observed tachycardia rate, usually
including a 2- or 3-zone arrhythmia detection scheme (as dis-
cussed elsewhere) [106]. Clinicians should allow a larger rate dif-
ferential when starting a patient on an antiarrhythmic drug that
might slow the clinical tachycardia rate (e.g., amiodarone).13. Single- or Multi-Zone Detection
Modern ICDs allow the rate to be classiﬁed into single or multiple
zones. This classiﬁcation permits different criteria to be applied for
detection (e.g., number of intervals) and for tiered therapy (e.g., dif-
ferent adaptive CLs for slower vs faster VTs andmore sequences of ATP
for slower and presumably hemodynamically more stable VTs).
Additionally, because some manufacturers tie SVT discrimination
algorithms to speciﬁc VT zones, programming more than one tachy-
cardia zone allows for greater speciﬁcity in discriminating VT from SVT
(see online Appendix B). Although there are trials in which arms differ
in whether a single zone or multiple zones are used, this is typically
performed to allow programming of various detection, discrimination,
or therapies for comparison. Thus, the number of zones was not the
randomization variable being directly compared. Therefore, the con-
cept of single- vs multizone programming as a head-to-head com-
parison is not well tested. The MADIT-RIT study randomized primary
prevention ICD patients into 1 of 3 arms with single-, dual-, or triple-
zone programming (the single-zone arm also had a monitoring zone).
Although the trial’s aim was to compare conventional therapy with
high-rate and delayed therapy, the outcome for the single-zone arm
(high-rate) was comparable to the triple-zone (delayed) arm and
superior to the dual-zone (conventional) arm, with regard to inap-
propriate shock [96]. This study is consistent with multiple studies in
ICD programming inwhich the use of multiple-zone programming has
allowed for ﬂexibility in programming strategies with regard to
detection, discrimination, and therapy. Additionally, there are obser-
vational data from the ALTITUDE Real World Evaluation of Dual-Zone
ICD and CRT-D Programming Compared to Single-Zone Programming
(ALTITUDE REDUCES) study that show that dual-zone programming isassociated with fewer shocks than single- zone programming, at least
for rates [64]. Therefore, the authors conclude that using more than
1 detection zone can be useful for modern ICD programming. It should
be noted that ATP before or during charging was used in the majority
of studies described in both the tachycardia detection and therapy
sections and thus is recommended for longer detection.14. Discrimination Between Supraventricular and Ventricular
Arrhythmia
The SVT-VT discrimination process classiﬁes a sequence of sensed
EGMs that satisﬁes rate and duration criteria as either SVT (therapy
withheld) or VT/VF (therapy given). Discriminators are individual
algorithm components that provide a partial rhythm classiﬁcation
or a deﬁnitive classiﬁcation for a subset of rhythms. Discrimination
algorithms combine individual component discriminators to produce a
ﬁnal rhythm classiﬁcation. Discrimination algorithms vary among
manufacturers and between individual ICD models (see online
Appendix B). The ﬁnal rhythm classiﬁcation can differ depending on
the technical details of how each individual discriminator is calculated,
the nominal or programmed threshold for each discriminator, the
order in which discriminator components are applied, and the logical
connections between them (e.g., “and” vs “or”). In some ICDs, rhythms
classiﬁed as VT/VF undergo a subsequent sensing-veriﬁcation step to
conﬁrm that EGMs represent true cardiac activation.15. SVT-VT Discriminator Components
Individual discriminators can be considered in relation to the
EGMs analyzed as ventricular-only or both atrial and ventricular,
by the rhythm that they identify (e.g., AF, sinus tachycardia, VT), or
by the type of EGM information analyzed (intervals vs morphol-
ogy). Note that ventricular rate alone is a mandatory discriminator,
as discussed in the section above. We summarize the most com-
monly used discriminators. More comprehensive discussions are
available in the literature [107–111].16. Rejection of Sinus Tachycardia by Onset
Several interval-based discriminators focus on differences in
the onset of sinus tachycardia (gradual and parallel acceleration of
atrial and conducted ventricular intervals) compared with VT
(typically abrupt, with at least transient atrioventricular dissocia-
tion). Sudden (abrupt) onset was one of the ﬁrst single-chamber,
interval-based discriminators. It withholds therapy if acceleration
across the sinus-VT rate boundary is gradual. Because onset dis-
criminators classify the rhythm only once, and thus cannot correct
misclassiﬁcations, they are now used infrequently and only with
an override feature and/or other discriminators [112–115].
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criminator that classiﬁes a 1:1 tachycardia as SVT if the atrial
rhythm accelerates at the device-deﬁned onset. A related “Sinus
Tachycardiaﬁ” discriminator classiﬁes a tachycardia as VT if either
the RR or the PR intervals deviate sufﬁciently from the range of the
immediately preceding sinus intervals [116].
16.1. Rejection of AF by Ventricular Interval Regularity
Ventricular interval regularity (interval stability) is an explicit
single-chamber, interval-based discriminator that classiﬁes the
rhythm as AF if the ventricular intervals are sufﬁciently irregular.
Because interval variability in conducted AF decreases at faster
rates, stability becomes unreliable in discriminating VT from
conducted AF at ventricular rates greater than 170 bpm [112,115].
Interval stability can also fail if drugs (e.g., amiodarone) cause
monomorphic VT to become irregular or induce polymorphic VT to
slow into the SVT-VT discrimination zone [114,117].
16.2. Diagnosis of VT by Dual-Chamber Components: Atrial vs Ven-
tricular Rate and Atrioventricular Association
In contrast to the single-chamber discrimination algorithms
above that diagnose SVT when their criteria are fulﬁlled, 2 separate,
interval-based, dual-chamber discrimination algorithms diagnose
VT. First, atrial rate vs ventricular rate diagnoses VT if the ven-
tricular rate exceeds the atrial rate [118]. s, atrioventricular dis-
sociation identiﬁes isorhythmic VT during sinus tachycardia.
Inversely, the atrioventricular association discriminator diagnoses
SVT in the presence of N:1 (e.g., 2:1, 4:1) atrioventricular association
consistent with atrial ﬂutter at a ﬁxed conduction ratio.
16.3. The Ventricular Electrogram Morphology Discriminator
This versatile, single-chamber discriminator is the only algo-
rithm component that does not rely on inter-EGM intervals. It
classiﬁes tachycardias as SVT if the morphology (shape) of the
ventricular EGM is sufﬁciently similar to the morphology during a
conducted baseline rhythm. It can potentially discriminate any SVT
from VT, including SVTs that challenge other discriminators, such as
abrupt-onset 1:1 SVTs and irregular VT during AF. Contemporary
ICDs (including subcutaneous ICD [S-ICD]) analyze EGMs from the
shock electrodes, which record a larger ﬁeld of view than EGMs
from pace-sense electrodes [119]. They operate using a common
series of steps and are susceptible to common failure modes
[111,120–123]. The ﬁrst common step is acquisition of a baseline
rhythm template by mathematically extracting EGM features and
storing them. Both the acquisition of the initial template and the
subsequent template updating are automated in most ICDs.
Nevertheless, physicians should conﬁrm that the conducted base-
line beats match the template both at implant and during follow-
up. For CRT patients, the template must be manually collected. If the
wavelet signal during template acquisition appears clipped,
adjustments speciﬁc to the manufacturer might be necessary.17. SVT-VT Discrimination Algorithms
Discrimination algorithms combine component discriminators
to provide a ﬁnal rhythm classiﬁcation of VT/VF or SVT. The mor-
phology discriminator frequently forms the primary component of
single-chamber algorithms with stability playing a secondary role
and sudden onset used sparingly. By contrast, the cornerstone of
most dual-chamber algorithms is explicit or implicit comparison of
atrial vs ventricular rates. Because the ventricular rate is greater
than the atrial rate in more than 80% of VTs, algorithms thatcompare atrial and ventricular rates as their ﬁrst step apply addi-
tional SVT discriminators to fewer than 20% of VTs, reducing the risk
that they will misclassify VT as SVT [124,125]. Most dual-chamber
algorithms further restrict single- chamber discriminators to
tachycardias for which they offer the greatest beneﬁt; thus, stability
is applied only if AF is conﬁrmed by direct calculation of the atrial
rate or the atrial rate is greater than the ventricular rate. Similarly,
sudden onset, chamber of onset, or 1:1 atrioventricular association
are applied only if the atrial rate equals the ventricular rate. The use
of discriminators in redetection varies among manufacturers and
has not been systematically studied.18. Assessing Clinical Beneﬁts and Risks
18.1. What Evidence Supports a Beneﬁt?. The annual rate of inappropriate shocks has fallen drama-
tically from 37%–50% for SVT alone in early studies to 1%–5%
for all causes in modern clinical trials [97,118,126–128]. This
decrease is likely due to differences in both clinical popu-
lations and the programming of multiple ICD parameters,
including longer detection time and higher rate cutoffs.
Thus, it is difﬁcult to isolate the differential effect of SVT-VT
discrimination algorithms using clinical data. These studies
have programmed discrimination algorithms to ON, how-
ever, so it seems reasonable to use them.. Although clinical trials that reported dramatic reductions in
shocks for SVT programmed discrimination algorithms
consistently, they have been programmed inconsistently in
clinical practice, and the rate of inappropriate shocks for SVT
has been higher in observational studies of remote- mon-
itoring ICD databases. In the ALTITUDE REDUCES study on
15,991 patients in the Latitudeﬁ database, SVT was the most
common cause of shocks when the detection rate was
r180 bpm [129]. For detection rates r170 bpm, the rate of
inappropriate shocks at 1 year was signiﬁcantly lower with
dual-zone programming, which permits SVT- VT dis-
crimination, than single-zone programming, which does not
(9.6% vs 4.3%). Similarly, Fischer et al [130] analyzed shocks
in 106,513 patients in the CareLinkﬁ database; programming
SVT-VT discrimination ON was associated with a 17%
reduction in all-cause shocks.. Sophisticated simulations indicate that SVT-VT discrimina-
tion algorithms have substantial beneﬁt. For example, the
SCD-HeFT study on primary prevention patients did not use
discriminators. A validated Monte Carlo simulation pre-
dicted that use of single- or dual-chamber SVT- VT dis-
criminators alone would have reduced inappropriate shocks
for SVT by 75.5% and 78.8%, respectively [131].18.2. Which Patients are Most Likely to Beneﬁt, and Which are Least
Likely to Beneﬁt?
Despite limited direct evidence, it seems clear that patients will
beneﬁt most if the rates of their VTs and SVTs overlap. This
includes patients with slower monomorphic VT, those at risk for
AF with rapid ventricular rates, or those capable of exercising to
sinus rates in the VT zonev [103,132]. In secondary prevention
patients with slower VT, older discrimination algorithms reduced
shocks for SVT compared with rate-only detection. The beneﬁt is
less for primary prevention patients, secondary prevention
patients at risk only for VF, and those who cannot sustain rapid
atrioventricular conduction. Patients with permanent complete
atrioventricular block do not beneﬁt.
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The risk of the misclassiﬁcation of either VT or VF as SVT by the
discrimination algorithms can either prevent VT detection or delay
the time to therapy (underdetection), as documented in clinically
signiﬁcant situations [112,113,115,125]. When modern algorithms
are programmed to recommended parameters, clinically sig-
niﬁcant underdetection is rare. Large clinical trials on multiple
shock-reduction strategies (including SVT-VT discrimination)
report no or minimal and statistically insigniﬁcant increases in
syncope [95,97,126,133]. Most reports do not include the causes of
syncope and thus do not permit identiﬁcation of whether dis-
crimination algorithms contributed to any of the syncopal epi-
sodes by prolonging detection. However, in the PREPARE study, no
syncopal episode was caused by untreated tachycardia [133]. In
general, discriminators that re-evaluate the rhythm classiﬁcation
during ongoing tachycardia reduce the risk of underdetection
compared with those that withhold therapy if the rhythm is
misclassiﬁed by the initial evaluation (e.g., onset, chamber of ori-
gin algorithms).19. Additional Considerations
19.1. SVT Limit
SVT-VT discrimination applies from the VT detection rate to the
SVT limit rate, which is programmable independently of the VT/VF
therapy zones with some manufacturers (preferable), but which
might be linked to one of the zone boundaries in others. The
minimum CL for SVT-VT discrimination should be set to prevent
clinically signiﬁcant delays in the detection of hemodynamically
unstable VT. PREPARE, EMPIRIC, and MADIT-RIT all support the
safety of empirical programming at 200 bpm [96,101,134]. In
MADIT-II, approximately 50% of SVT episodes were faster than
170 bpm, and a few were as fast as 250 bpm [82] In INTRINSIC RV,
SVT comprised 19% of episodes, with rates between 200 and
250 bpm [135]. More limited and preliminary data from PainFree
SST support programming up to 222–230 bpm [116,136]. We
suggest the SVT limit not exceed 230 bpm in adults without a
patient-speciﬁc indication, based on the low incidence of SVTs in
this rate range among ICD patients and the potential—however
small—for misclassifying hemodynamically unstable VT.
19.2. Duration-Based “Safety-Net” Features to Override
Discriminators
These features deliver VT/VF therapy if a tachycardia satisﬁes
the ventricular rate criterion for a sufﬁcient duration, even if the
discrimination algorithm indicates SVT. The premise is that the
ventricular rate during transient sinus tachycardia or AF will
decrease to below the VT rate boundary before the override
duration is exceeded. In one study, an override duration of
3 minutes delivered inappropriate therapy to 10% of SVTs [112].
Because SVT is much more common than VT, programming an
override duration of less than 5–10 minutes results primarily or
solely in inappropriate SVT therapy [122]. Although more data
would be useful, in the absence of a documented beneﬁt, we
recommend programming this feature OFF or long (minutes)
without a patient-speciﬁc or device-speciﬁc indication.
19.3. Dual-Chamber vs Single-Chamber Algorithms
Clinical trials and simulated testing of induced arrhythmias that
compared single- vs dual-chamber discriminators have reported
inconsistent results [10,33,137–139]. Two meta-analyses found nosuperiority of dual-chamber ICDs in terms of mortality or inap-
propriate therapies [11,140]. Any beneﬁt of dual-chamber dis-
crimination is likely restricted to speciﬁc patient groups [103,138].
For example, the Dual Chamber and Atrial Tachyarrhythmias
Adverse Events (DATAS) trial of predominantly secondary pre-
vention patients with slower VTs reported modest beneﬁt from
dual-chamber discrimination, while the recent Reduction and
Prevention of Tachyarrhythmias and Shocks Using Reduced Ven-
tricular Pacing with Atrial Algorithms (RAPTURE) trial of primary
prevention patients programmed to a fast detection rate
(4182 bpm) and long detection duration (30/40 intervals) did not
[103,138,139]. Inappropriate therapy for SVT occurred in only 2% of
the patients in each group. Recent data from PainFree SST notes
very low rates of inappropriate shocks (3.7% for single chamber;
2.8% for dual and triple chamber after 2 years). The choice of
device was not randomized, suggesting that when physicians
chose a dual- or triple- chamber device (perhaps due to known
atrial arrhythmia or bradycardia), inappropriate shock rates were
minimized [136]. The Optimal Anti-Tachycardia Therapy in
Implantable Cardioverter-Deﬁbrillator Patients Without Pacing
Indications (OPTION) trial randomized 462 patients to single- or
dual-chamber programming and noted inappropriate shock rates
of 10.3% for single chamber vs 4.3% for dual chamber after 27
months (P¼ .015). Atrial lead-related complications were 1.3%,
therapy was delivered from 170 bpm (VT) and 200 bpm (VF), and
no difference in ventricular pacing percentage was noted [141].
Dual-chamber algorithms probably reduce the risk of under-
detection compared with single- chamber algorithms because
more than 80% of VTs with a ventricular rate greater than the atrial
rate undergo no further analysis [103,124,125]. However, the rate
of clinically signiﬁcant underdetection with modern programming
is so low that this difference is rarely of clinical signiﬁcance. In
most patients, improved SVT-VT discrimination should not be
considered an indication for a dual- vs single-chamber ICD. Even if
a dual-chamber ICD is implanted, dual-chamber discrimination
should be programmed only if the atrial lead becomes chronic or if
atrial sensing is unreliable. Accurate sensing of atrial EGMs is
essential for dual-chamber SVT-VT discrimination. Atrial lead
dislodgments, oversensing of far-ﬁeld R waves, or undersensing
due to low-amplitude atrial signals can cause misclassiﬁcation of
VT/SVT. On implant, it is important to position the atrial lead to
minimize far-ﬁeld R waves.
19.4. Ventricular Oversensing
Excluding recalled leads, ventricular oversensing accounts for
less than 10% of inappropriate shocks, but it often results in
repetitive shocks and severe symptoms [82,142–144]. Recently
introduced features reduce inappropriate therapies from over-
sensing of physiologic T waves and nonphysiologic signals related
to pace-sense lead failures as discussed below.20. Programming to Reduce T-Wave Oversensing
The problem of T-wave oversensing relates to the basic
requirement that ICDs reliably sense VF, which is characterized by
RR intervals shorter than the normal QT interval and some EGMs
with low amplitudes and slew rates. Approaches to minimizing T-
wave oversensing include reprogramming ventricular sensitivity,
altering sensing bandwidth, and changing the sensing bipole
[109,123,145]. One manufacturer provides an algorithm that
withholds therapy after rate and duration criteria for VT/VF are
fulﬁlled if a speciﬁc pattern of T-wave oversensing is identiﬁed
[146]. T- wave oversensing rates vary based on device design;
using an appropriate high band-pass ﬁlter results in very low rates
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unpredictable, features that minimize T-wave oversensing should
be enabled proactively at implant, providing they do not cause
undersensing in VF [146].21. Lead-Related Oversensing
Oversensed signals caused by pace-sense lead failure have
speciﬁc interval patterns and EGM characteristics [145,147,148].
Present algorithms identify three features: (1) intervals can be too
short to represent successive ventricular activations; (2) such short
intervals are often transient and can be repetitive; and (3) in true
bipolar leads, oversensed signals are absent on the shock EGM.
Algorithms can provide warning alerts, withhold shocks after
spurious detection of VT/VF, or both. All 3 criteria can provide
alerts, but only the third is applied to withhold shocks. The present
algorithms were developed to identify impending lead failures on
recalled leads, notably the Sprint Fidelis. These algorithms might
not be appropriate for detecting failures in other leads [144]. There
is a high false-positive rate when using these algorithms, and
caregivers must carefully review the device data that caused the
alert to ensure the lead experienced a true failure [145].
Alerts that combine both oversensing and abrupt changes in
impedance trends provide earlier warning of lead failure than a
ﬁxed impedance threshold [144,145,149]. Such alerts can be
delivered via wireless remote monitoring and/or by notifying the
patient via vibration or an audible tone. Caregivers must respond
rapidly to alerts to minimize inappropriate shocks [144,149].
Wireless remote monitoring has been reported to reduce response
time [150]. The principal disadvantage of lead alerts is false-
positive triggers. The principal risk of shock-withholding algo-
rithms is a failure to shock VF, which is extremely rare [151]. In
addition to algorithmic approaches, oversensing due to failure of
the cable leading to the ring electrode can be prevented by
changing the programming of the sensing conﬁguration from true
bipolar to integrated bipolar. This approach is appropriate pro-
phylactically or as temporary programming after a ring electrode
cable failure; it is not a permanent solution, however, because
increased rates of high-voltage cable fractures have been docu-
mented after sensing cable fractures [152].F22. The Subcutaneous Deﬁbrillator (S-ICD)
The novel S-ICD follows many of the same principles as intra-
vascular ICDs but is considered here separately for duration cri-
teria, rate criteria, and discrimination algorithms. Candidates for
the S-ICD must initially be screened with a modiﬁed tri-channel
surface electrocardiogram that mimics the sensing vectors of the
S-ICD system. This test is designed to assess the R-wave to T-wave
ratio for appropriate signal characteristics and relationships. If the
screening is not satisfactory for at least 1 of the 3 vectors supine
and standing, an S-ICD should not be implanted. On implant, the
S-ICD automatically analyzes and selects the optimal sensing
vector.
Detection of VT or VF by the S-ICD is programmable using a single
or dual zone. In the single-zone conﬁguration, shocks are delivered for
detected heart rates above the programmed rate threshold: the “shock
zone” [134]. In the dual-zone conﬁguration, arrhythmia discrimination
algorithms are active from the lower rate: the “conditional shock
zone.” In this latter zone, a unique discrimination algorithm is used to
classify rhythms as either shockable or nonshockable. If they are
classiﬁed as supraventricular arrhythmias or nonarrhythmic over-
sensing, therapy is withheld.With dual-zone programming, the shock zone uses rate as the
sole method for rhythm analysis. In contrast, the conditional shock
zone uses a stepwise discrimination algorithm to distinguish
shockable from nonshockable rhythms. The conditional shock
zone has a morphology analysis process based on a normal rhythm
transthoracic QRS:T wave template. The template uses up to 41
ﬁduciary points to reconstruct morphology for the template as
well as the programmed targeted heart rate zones. The compar-
ison of the template to the high-rate rhythm electrocardiogram for
discrimination constitutes the static waveform analysis. A good
template match designates a sensed beat as supraventricular,
thereby preventing a shock. A poor match to the static QRS:T
morphology template moves the algorithm to a dynamic wave-
form analysis that compares single-beat morphologies in groups of
4 beats for uniformity. A consistent dynamic waveform match
adjusts the sensing to evaluate QRS width. If a tachycardia has a
prolonged QRS width compared with the template width
(420 ms) and is of sufﬁcient duration, it will lead to a shock.
The system uses an initial 18 of 24 duration criteria (non-
programmable) prior to initiating capacitor charging; however,
this duration is automatically extended following nonsustained
ventricular tachyarrhythmia events. A conﬁrmation algorithm is
also used at the end of capacitor charging to ensure persistence of
the ventricular arrhythmia prior to shock delivery. Shocks for
spontaneous (noninduced) episodes are delivered at a non-
programmable 80 J regardless of the therapy zone of origination.
When programmed to include a conditional shock zone, the S-
ICD VT detection algorithm has been demonstrated to be more
effective than transvenous ICD systems programmed at nominal
settings to prevent the detection of induced supraventricular
arrhythmias [153]. Furthermore, in the clinical evaluation of the
conditional shock zone, the S-ICD system was strongly associated
with a reduction in inappropriate shocks from supraventricular
arrhythmias and did not result in prolongation of detection times
or increased syncope [154].23. Integrating Tachycardia Detection Data Into Programming
Recommendations
When taking data from speciﬁc single-manufacturer studies
and producing generic guidelines applicable across all ICDs, some
compromises and potential pitfalls have been encountered.
Nevertheless, it is our intention to convey the general principles of
good quality evidence (e.g., extending detection time) to apply to
ICD programming in general. Thus, attempts have been made to
translate interval-based detection to time-based detection and to
provide a range of reasonable heart rate cutoffs that are inclusive
of those proven in good- quality trials. We encourage program-
ming ICDs to manufacturer-speciﬁc therapies of proven beneﬁt;
however, when evidence is lacking, the guidelines provide a fra-
mework for programming within the evidence base. See online
Appendix B for manufacturer-speciﬁc examples of optimal ICD
programming.Tachycardia Detection Program-
ming RecommendationsClass of Recom-
mendationLevel of
Evidenceor primary prevention ICD
patients, tachyarrhythmia
detection duration criteria
should be programmed to
require the tachycardia to con-
tinue for at least 6–12 seconds*
or for 30 intervals beforeI A
*F
*
F
*
D
*
It
F
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total therapies.
Tachyarrhythmia detection dura-
tion is directly related to the
tachyarrhythmia rate. Direct evi-
dence to support a delay 42.5
seconds for rates over 250 bpm is
not available, but can be inferred
from evidence that 30 detection
intervals are safe at that rate.*or primary prevention ICD
patients, the slowest tachy-
cardia therapy zone limit should
be programmed between 185
and 200 bpm*, to reduce total
therapies.I AItHigher minimum rates for detec-
tion might be appropriate for
young patients or for those in
whom SVT-VT discriminators
cannot reliably distinguish SVT
from VT, provided there is no
clinical VT below this rate.Wor secondary prevention ICD
patients, tachyarrhythmia
detection duration criteria
should be programmed to
require the tachycardia to con-
tinue for at least 6–12 seconds*
or for 30 intervals before com-
pleting detection, to reduce
total therapies.I B-RItTachyarrhythmia detection dura-
tion is directly related to the
tachyarrhythmia rate. Direct evi-
dence to support a delay 42.5
seconds for rates over 250 bpm is
not available, but can be inferred
from evidence that 30 detection
intervals are safe at that rate.Fiscrimination algorithms to dis-
tinguish SVT from VT should be
programmed to include
rhythms with rates faster than
200 bpm and potentially up to
230 bpm (unless contra-
indicated*) to reduce inap-
propriate therapies.I B-RP
It
ItDiscrimination algorithms and/or
their individual components are
contraindicated in patients with
complete heart block or if the
algorithm/component is known to
be unreliable in an individual
patient. Dual-chamber dis-
criminators that misclassify VT as
SVT if the atrial lead dislodges are
discouraged in the perioperative
period. Dual-chamber dis-
criminators are contraindicated
in patients with known atrial lead
dislodgment, atrial undersensing
or oversensing of far ﬁeld R
waves, and in those with perma-
nent AF.I B-NRis recommended to activate
lead-failure alerts to detect
potential lead problems.
or secondary prevention ICD
patients for whom the clinical
VT rate is known, it is reason-
able to program the slowest
tachycardia therapy zone at
least 10 bpm below the docu-
mented tachycardia rate but not
faster than 200 bpm*, to reduce
total therapies.IIa C-EOHigher minimum rates for detec-
tion might be appropriate for
young patients or for those in
whom SVT-VT discriminators
cannot reliably distinguish SVT
from VT, provided there is no
clinical VT below this rate.
can be useful to program more
than one tachycardia detection
zone to allow effective use of
tiered therapy and/or SVT-VT
discriminators and allow for a
shorter delay in time-based
detection programming for fas-
ter arrhythmias.IIa B-Rhen a morphology dis-
criminator is activated, it is
reasonable to reacquire the
morphology template when the
morphology match is unsa-
tisfactory, to improve the accu-
racy of the morphology
discriminator.IIa C-LDis reasonable to choose single-
chamber ICD therapy in pre-
ference to dual-chamber ICD
therapy if the sole reason for the
atrial lead is SVT discrimination,
unless a known SVT exists that
may enter the VT treatment
zone, to reduce both lead-
related complications and the
cost of ICD therapy.IIa B-NRor the S-ICD, it is reasonable to
program 2 tachycardia detection
zones: 1 zone with tachycardia
discrimination algorithms from
a rate r200 bpm and a second
zone without tachycardia dis-
crimination algorithms from a
rate Z230 bpm, to reduce
avoidable shocks.IIa B-NRrogramming a nontherapy zone
for tachycardia monitoring
might be considered to alert
clinicians to untreated
arrhythmias.IIb B-NRmay be reasonable to disable
the SVT discriminator timeout
function, to reduce inappropri-
ate therapies.IIb C-EOmay be reasonable to activate
lead “noise” algorithms that
withhold shocks when detectedIIb C-EO
It
It
*T
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shock or other far-ﬁeld channel
to avoid therapies for non-
physiologic signals.
may be reasonable to activate T-
wave oversensing algorithms, to
reduce inappropriate therapies.IIb C-LDmay be reasonable to program
the sensing vector from bipolar
to integrated-bipolar in true-
bipolar leads at risk for failure of
the cable to the ring electrode to
reduce inappropriate therapies.*IIb C-EOhis is not intended as a long-term
solution when a cable fracture
has been identiﬁed.24. Tachycardia Therapy Programming
Although therapies delivered by the ICD can abort SCD,
appropriate and inappropriate ICD shocks have been associated
with a considerable increase in the risk of mortality [82,83,155–
158]. In the Sudden Cardiac Death in Heart Failure Trial (SCD-
HeFT), the risk of mortality was 5-fold higher in patients who
received appropriate ICD shocks and 2-fold higher in patients who
received inappropriate shocks [83]. Similarly, pooling data from
4 studies of 2135 ICD patients, shocked VT was associated with a
32% increase in the risk of mortality. In that analysis, shocked
patients had poorer survival than patients treated with ATP only
[155]. ICD shocks are likely a marker of more advanced heart
disease and subsequent death, but deﬁbrillation therapies have
been associated with troponin release and increased LV dysfunc-
tion with the potential of further mortality risk.
The incidence of appropriate and inappropriate ICD shocks
depends on the patient’s characteristics, including the indication
for the device, concomitant medical therapies including antiar-
rhythmic medications, programming of the ICD, and the duration
of follow-up. With regard to ICD programming, faster VT/VF
detection rates, longer detection durations, use of a single zone,
use of SVT discriminators, and delivery of ATP have been shown to
reduce both appropriate and inappropriate shocks and to improve
quality of life [91,101,126,129,130,133,159,160]. This programming
might improve survival [126]. Indeed, several studies have shown
that ATP is effective at terminating slow and fast VT with
exceedingly low rates of adverse events like syncope [93,135,161–
165]. The initial bias of the ICD community was to reserve ATP
therapy for those patients in whom the therapy was demonstrated
to be effective, usually during an electrophysiologic study. How-
ever, the approach of physician-directed programming based on
the knowledge of induced arrhythmias was found to be sig-
niﬁcantly inferior to the routine strategic (EMPIRIC) programming
of ATP. It is not reﬂective of the arrhythmias experienced outside
the electrophysiology laboratory for primary and secondary pre-
vention patients with ischemic and nonischemic substrates
[101,166]. Although the ideal number of ATP bursts has not been
deﬁnitively determined, current data support the use of up to
2 ATP attempts, given additional attempts yield very little addi-
tional efﬁcacy [93,135,161–165,167,168]. In one study, up to
5 attempts were found to be safe [168]. The most effective ATP
duration is likewise uncertain; however, in the ATP Delivery for
Painless ICD Therapy (ADVANCE-D) trial—a prospective RCT of 925
patients—8-pulse ATP was as effective and safe as 15-pulse ATP
[169]. The PITAGORA ICD clinical trial randomized 206 patientswith an ICD to 2 ATP strategies: an 88% coupling interval burst vs a
91% coupling interval ramp. The results of the trial showed that
over a median follow-up of 36 months and compared with ramp
pacing, burst pacing was more effective for terminating fast VT
episodes (between CL 240 and 320 ms) [170]. In a prospective
study of 602 patients, a strategy of tiered ATP and low-energy
shock was efﬁcacious and safe in patients with VT CL greater than
250 ms, with extremely low syncope rates [171]. However, a “real-
world” retrospective study on 2000 patients with 5279 shock
episodes from the LATITUDE remote monitoring system showed
that the success rate of ﬁrst shock as ﬁrst therapy was approxi-
mately 90%, but the success rate was lower after failed ATP.
Therefore, that study recommended programming a higher level
of energy after ATP [172]. Finally, a substudy of the Effectiveness
and Cost of ICD Follow-Up Schedule with Telecardiology (ECOST)
study, which randomly assigned 433 patients to remote monitor-
ing (n¼221; active group) vs ambulatory follow-up (n¼212;
control group), showed that remote monitoring was highly effec-
tive in the long-term prevention of inappropriate ICD shocks
through early detection and prevention of AF with a rapid ven-
tricular rate, nonsustained VT, or diverted VT episodes [173].25. Beneﬁts and Risks
The goal of ICD therapy is to prolong life while causing as little
morbidity as possible. Although survival is quantiﬁably objective,
morbidity is more subjective and includes both physical and
emotional components. Clearly, shocks are usually painful to the
patient, whereas ATP is typically not uncomfortable. However,
there can be other morbidities related to both therapies, including
mild to extreme emotional distress, syncope, palpitations, and
proarrhythmia yielding more therapies and occasionally leading to
death. Paradoxically, the need for life-saving therapies, including
shocks and potentially ATP, might also be associated with
increased mortality; however, the causal relationships are unclear.
Also, the prevalence of tachycardia amenable to ATP or hemody-
namic signiﬁcance varies with the mechanism of the risk (e.g.,
long QT vs ischemic cardiomyopathy). In addition, although the
risk of having a hemodynamically important or life-threatening
arrhythmia can vary from patient group to patient group, the
largest proportion of patients in whom ICD therapy is applied has
yet to have a previously recorded arrhythmia, and we must
therefore strategically choose on the basis of other factors how we
will treat the ﬁrst event and subsequent events.26. Classiﬁcation of Therapy
The literature uses deﬁnitions of therapies that differ from each
other and that impact their results and conclusions. The occur-
rence rates of these events not only are dependent on their deﬁ-
nition but also are highly dependent on the programming of the
deﬁbrillation system. Both shock and nonshock therapies can be
categorized as being appropriate, inappropriate, and avoidable.
Whereas appropriate and inappropriate therapies refer to thera-
pies that were actually delivered, avoidable therapies are theore-
tical events in the future. These potential future tachycardia
therapies, delivered for either appropriately or inappropriately
detected events, can frequently be avoided by establishing pro-
gramming to either prevent the initiation of the arrhythmia or to
allow the condition to pass without therapy.
B.L. Wilkoff et al. / Journal of Arrhythmia 32 (2016) 1–281627. Appropriate
A response to a sustained ventricular arrhythmia (VT, VF) or
hemodynamically poorly tolerated arrhythmias (e.g., associated
with syncope, rate over 200 bpm, or hemodynamically compro-
mising supraventricular arrhythmias).28. Inappropriate
A response to signals generated by something other than sus-
tained ventricular arrhythmias or hemodynamically poorly toler-
ated arrhythmias. Possible signals include supraventricular
rhythms such as sinus tachycardia, AF, atrial ﬂutter, reentrant SVT,
atrial tachycardia, or instances of signal misinterpretation. Signal
misinterpretation includes multiple counting of single events (e.g.,
atrial, T-wave or R- wave), environmental signals such as electro-
magnetic interference, frequent premature ventricular contrac-
tions (PVCs) and nonsustained ventricular arrhythmias, extra-
cardiac physiologic signals (e.g., diaphragmatic or pectoral myo-
potentials), other implantable electronic devices (e.g., pacemakers,
LV assist devices, nerve stimulators), inappropriate lead placement
or dislodgment, conductor or insulation failures, header connec-
tion instability, and pulse generator failure.29. Avoidable
Programming of detection and therapy parameters and algo-
rithms so that shock or ATP therapy is withheld from arrhythmias
that would be expected to be hemodynamically tolerated. Exam-
ples include self-terminating ventricular arrhythmias, ATP-
susceptible ventricular arrhythmias, and overdrive suppression
responsive rhythms. Many appropriate and most inappropriate
therapies are also potentially avoidable.30. Phantom
These are not true therapies; however, there is the patient’s
perception that a therapy was delivered. Interrogation of the ICD
and/or coincident rhythm monitoring does not identify a tachy-
cardia or therapy.31. Unintended Consequences of ICD Therapy and ICD Therapy
Programming
In the SCD-HeFT and MADIT II trials, inappropriate shocks more
than doubled the risk of death. Mortality rates were substantially
higher after shocks: 10% within days after the ﬁrst shock, 25%
within 1 year, and 40% by 2 years. The leading cause of death was
progressive HF. In an analysis of the MADIT-CRT trial, the patients
with appropriate shocks experienced increased mortality when
compared with the patients without ICD shocks, after accounting
for mechanical remodeling effects; this was not the case for
patients who received appropriate ATP only [156]. ICD shocks have
also been associated with independent predictors of mortality in
the large ALTITUDE registry of 3809 ICD recipients and in a meta-
analysis of ICD trials in which ATP was applied [155,157]. Emo-
tional morbidities associated with ICD shocks are well recognized
and include anxiety, depression, and posttraumatic stress dis-
orders [174–176]. Phantom shocks can result from fear and/oranxiety and have a reported incidence of 5% in a European study of
ICD recipients over 35 months of follow-up [177]. If possible, and
when safe, it is best to avoid both the discomfort and psychological
impact of shocks for ventricular arrhythmias, supraventricular
arrhythmias, noise events including lead failures, and for self-
terminating arrhythmias, as is discussed in the section on tachy-
cardia detection. The 1500-patient MADIT-RIT study demonstrated
a mortality reduction by changing both tachycardia detection cri-
teria and tachycardia therapy (shocks and ATP). Therefore, it is
difﬁcult to assign the outcome result to ATP, shocks, or both when
compared with older, more conventional programming [126]. In
addition, in a randomized study of remote follow-up of ICDs, home
monitoring showed an incidence of 52% fewer inappropriate
shocks, 72% fewer hospitalizations due to inappropriate shocks,
76% fewer capacitor charges, and a signiﬁcant positive impact on
battery longevity [178].31.1. ATP
Several large clinical trials have established the safety and
efﬁcacy of ATP as a ﬁrst-line therapy to treat even very fast VTs
[93,95,101,133]. The use of ﬁrst-line ATP involving VT at rates
between 188 and 250 bpm in the PainFREE Rx II trial resulted in a
71% relative shock reduction [93]. In the PREPARE study, a primary
prevention cohort of 700 patients was programmed with 30 of 40
detection intervals with ATP- ﬁrst for VT between 182 and
250 bpm with SVT discriminators active up to 200 bpm. The
results demonstrated a robust absolute risk reduction for shocks at
1 year from 17% to 9% without an increase in arrhythmic syncope
when compared with historical controls [133]. Similar ﬁndings
were noted in the RELEVANT study, which evaluated a cohort of
patients with nonischemic heart disease and cardiac resynchro-
nization deﬁbrillators [95]. In the earlier EMPIRIC study, standar-
dized VT detection and ATP therapy parameters demonstrated a
reduction in shocks when compared with physician-tailored
treatment in a randomized assessment of 900 primary preven-
tion patients [101]. The use of ATP during ICD capacitor charging
has been clinically validated as safe and effective [163]. It is
important to recognize that inappropriate therapies including
inappropriate ATP, delivered primarily in the setting of supraven-
tricular arrhythmias, have been associated with increased mor-
tality in the MADIT-RIT and MADIT-CRT trials [156,179]. However,
the overall safety of ATP and its role as a contributor to improved
survival are well established, particularly in terms of preventing
avoidable ICD shocks.31.2. Customized vs Strategic Programming
Because primary prevention patients have no prior ventricular
arrhythmias, programming individual devices on implant is largely
empiric. There are more data for secondary prevention patients,
but how the patient will behave in the future is still uncertain. The
ability to individualize the antitachycardia programming for
patients with both primary and secondary prevention indications
was tested in the EMPIRIC trial and found to be an inferior
approach to prevent these therapy events [101]. The application of
standardized programming and borrowing data from the PainFREE
Rx II and PREPARE studies resulted in a comprehensive review of
programming and its application across manufacturers.
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For the secondary prevention ICD patient, speciﬁc knowledge
of the patient’s arrhythmia history facilitates the creation of an
effective antitachycardia programming strategy. Using what is
known about the ventricular arrhythmia, including any electro-
cardiograms, available telemetry strips, and EMS recordings, pro-
vides insight into the arrhythmia mechanism. In cases of mono-
morphic VT, discerning the rate (CL) and the hemodynamic impact
is useful in making choices, particularly for detection at a mini-
mum; the device must be programmed with active VT detection
zones sufﬁcient to cover the clinical arrhythmia. Slower, mono-
morphic VT that is better tolerated hemodynamically favors a
robust approach using ATP termination with at least 2–3 sequen-
ces and at least 8 pulses. The use of a second burst of ATP has also
been shown to increase effectiveness from 64% to 83% in the fast
VT range of 188 to 250 bpm [167]. Although a second burst has
clear value, value beyond 2 bursts is limited, except in rare situa-
tions [101]. The use of ICDs in patients with implanted LV assist
devices allows prolongation of detection times and programming
of multiple ATP attempts without signiﬁcant risk to the patient,
and it reduces the opportunity for shock therapies. Adjunct med-
ications and ablation of VT (or SVT) might also be considered for
cases in which slow VT occurs or if there is an overlap between the
SVT and VT rates, leading to ICD therapies.It
It
It
ItTachycardia Therapy Program-
ming RecommendationsClass of Recom-
mendationLevel of
Evidenceis recommended in all patients
with structural heart disease
and ATP-capable ICD therapy
devices that ATP therapy be
active for all ventricular
tachyarrhythmia detection
zones to include arrhythmias up
to 230 bpm, to reduce total
shocks except when ATP is
documented to be ineffective or
proarrhythmic.I Ais recommended in all patients
with structural heart disease
and ATP-capable ICD therapy
devices that ATP therapy be
programmed to deliver at least
1 ATP attempt with a minimum
of 8 stimuli and a cycle length of
84%–88% of the tachycardia
cycle length for ventricular
tachyarrhythmias to reduce
total shocks, except when ATP is
documented to be ineffective or
proarrhythmic.I Ais indicated to program burst
ATP therapy in preference to
ramp ATP therapy, to improve
the termination rate of treated
ventricular tachyarrhythmias.I B-Ris reasonable to activate shock
therapy to be available in all*
ventricular tachyarrhythmia
therapy zones, to improve the
termination rate of ventricular
tachyarrhythmias.IIa C-EOarely, to limit patient discomfort
and anxiety, hemodynamically
stable slow VT can be treated
without programming a backup
shock.
is reasonable to program the
initial shock energy to the
maximum available energy in
the highest rate detection zone
to improve the ﬁrst shock ter-
mination of ventricular
arrhythmias unless speciﬁc
deﬁbrillation testing demon-
strates efﬁcacy at lower
energies.IIa C-LD32. Intraprocedural Testing of Deﬁbrillation Efﬁcacy
The efﬁcacy of the ICD for the primary and secondary preven-
tion of SCD has been well established in several landmark clinical
trials [180–185]. Most of these trials have required induction,
detection, and termination of VF at the time of implantation as a
measure of deﬁbrillation efﬁcacy and as a surrogate of the ICD’s
ability to prevent SCD. Testing deﬁbrillation efﬁcacy has been
considered an integral part of ICD implantation for many years,
and it is performed to establish the appropriate connection of
high-voltage electrodes and to test the ability of the ICD to detect
and terminate VF with a shock. However, identifying system fail-
ures or high deﬁbrillation thresholds is difﬁcult, mainly due to the
low prevalence, which also depends on the deﬁnition employed,
about 5% combined. Signiﬁcant improvements over the past
2 decades have reduced energy requirements for deﬁbrillation
[186–189]. Similarly, current transvenous ICD technology is cap-
able of delivering energies of 35–40 J, raising the question of the
value of routine deﬁbrillation testing (DT). Physicians have there-
fore gravitated to implanting ICDs with minimum or no DT with
wide variability in practice, despite a paucity of rigorous data. DT is
currently being performed during ICD implant in only about half
the procedures [190–195]. Studies evaluating DT are summarized
in Table 4.
One of the most important reasons to avoid DT at the time of
ICD implantation is that testing might result in complications or
even death. The risks of DT include (1) those related to VF itself,
which can lead to circulatory arrest and hypoperfusion, (2) risks
related to the shocks delivered to terminate VT, and (3) risks
related to anesthetic drugs that are required for heavier sedation,
which are used to provide patient comfort during testing.33. Periprocedural Mortality
Although improved ICD technology has led to the need for
fewer inductions of VF at the time of implantation testing,
procedure-related mortality has not been completely eliminated.
Using modern ICD technology with transvenous systems and
biphasic waveforms, the perioperative mortality rate within 30
days of implantation is reported to be 0.2% to 0.4% [191,196].
Recent data from the National Cardiovascular Data Registry
(NCDR) demonstrated an in-hospital mortality of 0.03% following
ICD implantation, with death occurring in the laboratory in 0.02%
[196]. A Canadian report from 21 implanting centers estimates that
3 of 19,067 deaths (0.016%) are related to DT.
Table 4
Deﬁbrillation testing.
Study (n) Patients (DT/
no DT)
Results and remarks
CREDIT [193] 64%/36% More frequent DT for new implants vs generator replacements (71% vs 32%, P¼ .0001), DT for primary and secondary
prevention indications (64% vs 63%, P¼NS).(361)
Prospective multicenter
registry
Reasons for no DT were as follows: unnecessary (44%); persistent atrial ﬁbrillation (37%); no anesthetist (20%); and
patient or physician preference (6%).
DT was not performed in a third of ICD implants, usually due to a perceived lack of need or relative contraindication.
Nonconsecutive patients, single manufacturer.
Ontario DT Registry [225] PP: 65%/45% Multivariate predictors for DT included new ICD implant (OR 13.9; P P P¼ .004), and LVEF 420% (OR 1.3; P¼ .05). History
of AF (OR 0.58; P¼ .0001) or OAC use (OR: 0.75; P¼ .03) was associated with a lower likelihood of having DT. Compli-
cations, including death, were similar: DT 8.7% vs no DT 8.3% (P¼ .7).
(2173) SP: 67%/43%
Prospective multicenter
registry
GR: 24%/
76% All consecutive implants at 10 centers in Ontario
NCDR [223] 71%/29% No DT; older, higher incidence of HF, lower LVEF, atrial arrhythmias, and a primary prevention indication; hospital
adverse events; DT 2.56% vs. 3.58% no DT (P P(64,277)
Prospective multicenter
registry
Generator replacement excluded.
Israel DFT Registry [226] 17%/83% Variables associated with ICD testing: implantation for secondary prevention (relative risk [RR] 1.87), prior ventricular
arrhythmias (RR 1.81), use of AADs (RR 1.59), and sinus rhythm (RR 2.05). No signiﬁcant differences in the incidence of
mortality, malignant ventricular arrhythmias, or inappropriate ICD discharges were observed between patients who
underwent DT compared with those who were not tested.
(3596)
Prospective multicenter
registry
All consecutive implants during 1 year at 22 centers: HOCM: 6.2% DT, 6.3% no DT; ARVC: 0.6% DT, 0.5% no DT; congenital
heart disease: 0.8% DT, 2.1% no DT; Long QT: 1.2% DT, 0.26% no DT; Brugada syndrome: 0.3% DT, 0.44% no DT; family
history cardiac death: 5.3% DT, 4.7% no DT.
SAFE-ICD [210] 836 DT Followed up for 24 months. Primary endpoint was composite of severe implant complications, sudden cardiac death, or
resuscitation at 2 years.2120 1284 no DT
Prospective observational
study
Primary endpoint: Of 34 patients, 12 intraoperative complications (8 in DT; 4 in no DT) and 22 during follow-up (10 in
DT; 12 in no DT). Estimated yearly incidence: DT 1.15% (0.73 to 1.83) and no DT 0.68% (0.42 to 1.12); no difference.
In 41 Italian centers. The only exclusion criterion was refusal to provide consent. Other ICD indications: 15% DT, 12% no
DT.
Healey JS, et al [212] 75 DT All patients in DT arm achieved a successful DT (r25 J); 96% without requiring any system modiﬁcation. No patient
experienced perioperative stroke, myocardial infarction, HF, intubation, or unplanned ICU stay. The composite of HF
hospitalization or all-cause mortality occurred in 10% of no DT vs. 19% of the DT arm (HR: 0.53; 95% CI 0.21–1.31; P¼ .14).
(145) 70 no DT
Randomized Multicenter
subgroup study Conclusions: Perioperative complications, failed appropriate shocks, and arrhythmic death are uncommon regardless of
DT. There was a nonsigniﬁcant increase in the risk of death or HF hospitalization with DT.
Excluded: intracardiac thrombus, persistent or permanent AF without appropriate anticoagulation, right-sided implant,
or felt ineligible for DT.
SIMPLE [215] 1253 DT Primary outcome: arrhythmic death or failed appropriate shock occurred in fewer patients (90 [7% per year]) in no DT vs
DT (104 [8% per year]; HR 0.86; 95% CI 0.65–1.14; P noninferiority P¼ .33). The second safety composite outcome,
including only events most likely to be directly caused by DT, occurred in 3.2% of patients without DT vs 4.5% with DT
(P¼ .08).
2500 1247 no DT Routine DT at the time of ICD implantation is generally well tolerated but does not improve shock efﬁcacy or reduce
arrhythmic death.
Randomized multicenter trial Single manufacturer, excluded patients on active transplantation list, ICD expected to be right- sided implant. HOCM:
4.2% DT, 3.4% no DT; long QT, Brugada syndrome, or catecholaminergic polymorphic VT: 2.3% DT, 1.9% no DT.
NORDIC ICD [216] 540 DT ICD shocks were programmed to 40 J in all patients. Primary endpoint: ﬁrst shock efﬁcacy for all true VT and ﬁbrillation
episodes during 22.8 months of follow-up. Noninferior with or without DT. First shock efﬁcacy 3.0% in favor of no DT. A
total of 112 procedure-related serious adverse events occurred within 30 days in 94 DT patients (17.6%) and 89 events in
74 no-DT patients (13.9%).
1077 537 no DT
Randomized multicenter trial
Excluded were the following: survived an episode of VF due to acute ischemia or potentially reversible causes, listed for
heart transplant, life expectancy less than the study duration due to malignant conditions, terminal renal insufﬁciency,
any conditions precluding DT (e.g., left atrial or ventricular thrombus), preexisting or previous ICD or CRT-D, or if the
device was intended to be implanted on the right side.
Intraprocedural Testing of Deﬁbrillation Efﬁcacy Recommendations Class of
Recommendation
Level of
Evidence
Deﬁbrillation efﬁcacy testing is recommended in patients undergoing a subcutaneous ICD implantation. I C-LD
It is reasonable to omit deﬁbrillation efﬁcacy testing in patients undergoing initial left pectoral transvenous ICD implantation
procedures where appropriate sensing, pacing, and impedance values are obtained with ﬂuoroscopically well-positioned RV leads.
IIa B-R
Deﬁbrillation efﬁcacy testing is reasonable in patients undergoing a right pectoral transvenous ICD implantation or ICD pulse
generator changes.
IIa B-NR
Deﬁbrillation efﬁcacy testing at the time of implantation of a transvenous ICD should not be performed on patients with a docu-
mented nonchronic cardiac thrombus, atrial ﬁbrillation or atrial ﬂutter without adequate systemic anticoagulation, critical aortic
stenosis, unstable CAD, recent stroke or TIA, hemodynamic instability, or other knownmorbidities associated with poor outcomes.
III (Harm) C-LD
AAD¼antiarrhythmic drug; ARVC¼arrhythmogenic right ventricular cardiomyopathy; CAD¼cpronary heart disease; HOCM¼hypertrophic obstructive cardiomyopathy;
ICU¼ intensive care unit; OAC¼oral anticoagulant
B.L. Wilkoff et al. / Journal of Arrhythmia 32 (2016) 1–281834. DT-Related Complications
Complications occurring during ICD implantation procedures
are infrequent, and many can be directly or indirectly related to
DT. Adverse effects related to DT include myocardial injury,
depression of contractile function leading to worsening of HF,persistent hypotension, central nervous system injury, throm-
boembolic events, or respiratory depression.
Transient central nervous system hypoperfusion and cerebral
ischemic changes can be demonstrated during intraoperative
electroencephalographic (EEG) monitoring at the time of DT.
However, EEG recovery occurs within less than 30 seconds, with a
B.L. Wilkoff et al. / Journal of Arrhythmia 32 (2016) 1–28 19slightly longer time to the return of middle cerebral blood ﬂow
[197–199]. However, the clinical relevance of this transient ﬁnding
is unclear because DT does not appear to cause cognitive dys-
function 24–48 hours following ICD implantation [200,201].
Although an increase in biochemical markers of myocardial injury
can be observed during ICD implantation or after spontaneous
clinical shocks, true intraoperative myocardial infarction (MI) is
rare, even when extensive DT is performed [202–205]. In 2 recent
studies using transvenous ICDs and a more abbreviated testing
protocol, there was no signiﬁcant increase in CK, CK-MB, myo-
globin, and NT-proBNP before and after DT, whereas elevated
levels of high-sensitive troponin T were observed after DT
[206,207]. In the NCDR ICD Registry, the incidence of MI during
ICD implantation was reported to be 0.02% [196].
Deﬁbrillator shocks and VF transiently depress contractile
function, although fatal pulseless electrical activity is rare at the
time of ICD implantation [202,206,208–210]. Refractory VF has
been reported to occur during DT, but this is also uncommon,
particularly with contemporary devices. One study reported that
all tested ICD shocks failed and at least 3 external rescue shocks
were required in 0.5% of patients [203]. A Canadian study reported
that 27 of 19,067 implants (0.14%) required prolonged resuscita-
tions during DT [211].
Thromboembolic complications can occur during DT in the
presence of intracardiac thrombus or when there are less than
3 weeks of therapeutic and uninterrupted anticoagulation in the
setting of AF. Stroke or transient ischemic attack (TIA) is reported
to occur in 0.026%–0.05% of cases [204,211]. Multiple strategies
have been employed, but none were documented to reduce the
incidence of thromboembolism, including the avoidance of DT.
These include preprocedure transesophageal echocardiography to
exclude left atrial appendage thrombus and deferring testing
when a thrombus is identiﬁed, or using transthoracic echo-
cardiography to detect LV thrombi.
Anesthetic agents can contribute to complications related to a
depressant effect on myocardial contractility or can lead to respiratory
depression if oversedation occurs. Heavier sedation is typically used in
patients undergoing DT. Although patients with underlying chronic
obstructive pulmonary disease or sleep apnea might be at increased
risk, oversedation and respiratory depression could occur in any
patient. Randomized trial data can help to identify which adverse
events are directly (or indirectly) related to DT. For example, stroke or
TIA might be “directly” related to DT due to dislodgment of intra-
cardiac thrombus during conversion of AF in the absence of ther-
apeutic anticoagulation, and an episode of prolonged hypotension
could result in reduced cerebral perfusion. Respiratory depression,
respiratory failure requiring intubation, or hypotensionmight be direct
results of DT or might be due to the drugs required to perform testing.
Pulseless electrical activity or even death can occur with hemody-
namic complications related to induction of VF or multiple external
shocks. In contrast, DT can indirectly increase the risk for pneu-
mothorax, perforation, tamponade, lead dislodgment, or infection as
more leads are inserted, or the procedure might be prolonged due to
the system modiﬁcations required to improve deﬁbrillation efﬁcacy;
however, all these complications can also occur in the absence of DT.
In addition, due to the rates and types of adverse events reported in
the literature, it appears that overall complication rates are primarily
driven by mechanical complications or infection, most of which are
not related to DT.
In a substudy of the Resynchronization for Ambulatory Heart
Failure Trial (RAFT), in which 145 patients were randomized to DT
compared with no DT at the time of initial ICD implantation, the
risk of perioperative complications was extremely low, regardless
of DT performance [212]. There was, however, a nonsigniﬁcant
increase in the risk of death or HF hospitalization in the group that
underwent DT. Likewise, no signiﬁcant difference in implant-related complications was demonstrated in DT compared with
the groups without DT in the Safety of Two Strategies of ICD
Management at Implantation (SAFE-ICD) study, a prospective
observational study of 2120 patients performed at 41 centers
[213]. Similar ﬁndings were observed in the prospective rando-
mized Test-No Test Implantable Cardioverter Deﬁbrillator (TNT-
ICD) pilot study on 66 patients, in which there was no difference in
adverse events between patients who underwent testing com-
pared with those who did not [214].
The Shockless Implant Evaluation (SIMPLE) trial is the largest ran-
domized study assessing the effect of DT on clinical outcomes [215].
This large-scale study randomized 2500 patients to DT or not at the
time of ICD implantation; 1253 patients were randomly assigned to DT
and 1247 were assigned to no-testing, and were followed for a mean of
3.1 years (SD 1.0). The primary outcome of arrhythmic death or failed
appropriate shock was noninferior (90 [7% per year]) in the no-testing
group compared with patients undergoing DT (104 [8% per year]; HR
0.86; 95% CI 0.65–1.14; P noninferiority P¼ .33). The second, pre-
speciﬁed safety composite outcome, which included only events most
likely to be directly caused by testing, occurred in 3.2% of patients with
no testing and in 4.5% with DT (P¼ .08). Heart failure needing intra-
venous treatment with inotropes or diuretics was the most common
adverse event (in 20 of 1236 patients [2%] in the no-testing group vs 28
of 1242 patients [2%] in the testing group, P¼ .25). In summary, routine
DT at the time of ICD implantation is generally well tolerated without a
statistically signiﬁcantly increased rate of complications, but it also does
not improve shock efﬁcacy or reduce arrhythmic death.
Finally, the No Regular Deﬁbrillation Testing In Cardioverter
Deﬁbrillator Implantation (NORDIC-ICD) trial, another prospective
randomized parallel group multicenter noninferiority trial con-
ducted in 48 centers in Europe, assessed the effects of DT at the
time of ICD implantation on ﬁrst shock efﬁcacy [216]. The primary
endpoint was different from the SIMPLE trial and assessed the
average ﬁrst- shock efﬁcacy for all true VT and VF episodes
occurring in any patient during follow-up. NORDIC-ICD rando-
mized 540 patients to DT and 537 to no DT at the time of ICD
implantation. During a median follow-up of 22.8 months, the ﬁrst
shock efﬁcacy was demonstrated to be noninferior in the patients
undergoing ICD implantation without DT, with a difference in ﬁrst
shock efﬁcacy of 3.0% in favor of the no- DT test group (95% CI
3.0%–9.0%; P noninferiority procedure-related serious adverse
events were reported within 30 days of ICD implantation in 94
patients (17.6%) undergoing DT compared with 74 patients (13.9%)
not undergoing DT (P¼ .095). The authors concluded that deﬁ-
brillation efﬁcacy without DT was noninferior to ICD implantation
with DT in left-sided ICD implants. Because no major beneﬁt or
harm associated with DT was detected, in patients with a left-
sided pectoral implantation it is reasonable to omit routine VF
induction and DT during ICD implantation, assuming stable ICD
lead position and good sensing and capture function [217–220].
This approach is particularly applicable to patients with ischemic
and idiopathic dilated cardiomyopathy, given these entities were
well represented in the studied cohort. Patients well represented
within the cohort included those with implantation in the left
pectoral location, those indicated for primary and secondary pre-
vention of SCD, and patients with ischemic and nonischemic car-
diomyopathies. Fewer data are available regarding other cardio-
myopathies, such as patients with hypertrophic obstructive car-
diomyopathy, congenital channelopathies, patients undergoing
generator replacement, and procedures in the right pectoral
location. In these instances, and when there is any question of the
adequacy of the lead position or function, DT is reasonable. It is
worth emphasizing that a nontesting strategy requires an anato-
mically well- positioned deﬁbrillation lead in the RV with ade-
quate sensing of intrinsic R waves (45–7 mV), adequate pacing
thresholds, and a thorough veriﬁcation of proper lead connection.
B.L. Wilkoff et al. / Journal of Arrhythmia 32 (2016) 1–2820Other important considerations include the use of alternative RV
deﬁbrillation lead sites such as the mid-septum. Pooled data from
2 randomized studies do not indicate a clinically relevant elevation of
energy required for deﬁbrillation with mid-septal sites. Positioning of
the RV deﬁbrillation lead in other positions such as the RV outﬂow
tract has not been systematically addressed [221].
The SIMPLE trial data were consistent between subgroups, both
from patients with single- or dual-coil ICD leads and with or
without the use of amiodarone. More recently, the Multicenter
Comparison of Shock Efﬁcacy Using Single vs Dual-Coil Lead Sys-
tems and Anodal vs Cathodal Polarity Deﬁbrillation in Patients
Undergoing Transvenous Cardioverter-Deﬁbrillator Implantation
(MODALITY) study was reported [222]. This was a multicenter
registry that prospectively followed 469 consecutive patients
undergoing DT at the time of implant; 158 (34%) had dual- coil and
311 (66%) had single-coil lead systems conﬁguration, 254 (54%)
received anodal shock, and 215 (46%) received cathodal shock. In
35 patients (7.4%), the shock was unsuccessful. No signiﬁcant dif-
ferences in the outcome of DT using a single- vs dual-coil lead
were observed, but the multivariate analysis showed an increased
risk of shock failure using cathodal shock polarity (odds ratio [OR]
2.37; 95% CI 1.12–5.03). These and other registry data support the
use of either single- or dual-coil leads, preferably programmed to
deliver anodal shocks [211,213,223].
Performing DT has not been determined to be harmful or
inappropriate. One reason to perform DT in speciﬁc populations is
that high deﬁbrillation thresholds have been reported in 2.2% to
12% of subjects undergoing DT. The probabilistic nature of DT with
the failure of a single shock 10 J below the maximum ICD output
does not necessarily imply long-term ICD failure. Determinations
of DT using multiple shock protocols have reported that a safety
margin of only 5.2–1.1 J has a 97.3% rate of successful VT/VF con-
version [224]; however, the inability to convert VF at maximum
output occurs in approximately 1% of procedures during DT. The
long-term outcomes of these patients have not been evaluated
without modiﬁcation of the lead system. Further supporters of DT
suggest that routine testing is necessary to identify system integ-
rity and sensing failures. R-wave amplitude r5–7 mV at implant
almost invariably reliably sense VF [190,221]. Failure to sense and
some inner insulation failures might only be detected by DT. This
situation has not been systematically evaluated.Table A1
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